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Azithromycin 
Indications/Dosage
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Labeled
• bacterial conjunctivitis
• bronchitis
• chancroid
• chlamydia infection
• community-acquired pneumonia
• gonorrhea
• Mycobacterium avium complex (MAC)
prophylaxis
• Mycobacterium avium complex infection
• non-gonococcal urethritis (NGU)
• otitis media
• pelvic inflammatory disease (PID)
• pharyngitis
• pneumonia
• sinusitis
• skin and skin structure infections
• tonsillitis
Off-Label
• babesiosis †
• bartonellosis †
• bartonellosis prophylaxis †
• campylobacteriosis †
• chlamydial infection prophylaxis †
• cholera †
• coronavirus disease 2019 (COVID-19) †
• cystic fibrosis †
• dental abscess (apical) †
• dental abscess (periapical) †
• dental infection †
• dentoalveolar infection †
• endocarditis prophylaxis †
• gonorrhea prophylaxis †
• granuloma inguinale †
• Lyme disease †
• lymphogranuloma venereum †
• ophthalmia neonatorum †
• pertussis (whooping cough) †
• pertussis prophylaxis †
• rheumatic fever prophylaxis †
• severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection †
• shigellosis †
• syphilis †
• traveler's diarrhea †
• typhoid fever †
† Off-label indication
Per the manufacturer, this drug has been shown to be active against most strains of the 
following microorganisms either in vitro and/or in clinical infections:
Bacteroides bivius, Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, CDC coryneform group G, 
Chlamydia trachomatis, Chlamydophila pneumoniae, Clostridium perfringens, Haemophilus ducreyi, Haemophilus 
influenzae (beta-lactamase negative), Haemophilus influenzae (beta-lactamase positive), Legionella pneumophila, 
Moraxella catarrhalis, Mycobacterium avium, Mycobacterium intracellulare, Mycoplasma hominis, Mycoplasma 
pneumoniae, Neisseria gonorrhoeae, Peptostreptococcus sp., Prevotella bivia, Staphylococcus aureus (MSSA), 
Streptococcus agalactiae (group B streptococci), Streptococcus mitis, Streptococcus pneumoniae, Streptococcus 
pyogenes (group A beta-hemolytic streptococci), Streptococcus sp., Treponema pallidum, Ureaplasma urealyticum, 
Viridans streptococci. 
NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not been 
established in adequate and well-controlled clinical trials.
This drug may also have activity against the following microorganisms:
Bacillus anthracis, Gardnerella vaginalis, Helicobacter pylori, Klebsiella granulomatis, Mycoplasma genitalium, 
Rickettsia tsutsugamushi, Salmonella typhi, Staphylococcus epidermidis, Streptococcus sp. (Group C), Streptococcus 
sp. (Group F), Streptococcus sp. (Group G), Toxoplasma gondii, Vibrio cholerae. 
NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this list does 
not necessarily negate the drug’s activity against the organism.
INVESTIGATIONAL USE: For adjunctive use in the treatment of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the virus that causes 
coronavirus disease 2019 (COVID-19)†
Oral dosage (immediate-release)
• Adults
Data are limited and inconclusive. Due to the potential for toxicities, the National Institutes of Health (NIH)
COVID-19 treatment guidelines recommend against the use of azithromycin in combination with
hydroxychloroquine outside of clinical trials.[65314] Azithromycin is being used in some COVID-19 institutional
protocols. 500 mg PO on day 1 then 250 mg PO once daily for 5 days was administered in combination with
hydroxychloroquine in a small study. On day 6, all patients treated with hydroxychloroquine and azithromycin (n
= 6) were virologically cured compared to 57.1% of patients treated with hydroxychloroquine alone (n= 20).
[65147] Another small study (n = 11) reviewed the same azithromycin plus hydroxychloroquine regimen and
found nasopharyngeal swabs were still positive for SARS-CoV-2 in 8 of 10 patients at 5 to 6 days after
treatment initiation.[65198] In a retrospective analysis of a multicenter cohort study (n = 349) in patients with
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), 136 patients received macrolide therapy in
combination with antiviral treatment. Macrolide therapy was not associated with a reduction in 90-day mortality
compared to the control group (adjusted OR: 0.84; 95% CI: 0.47 to 1.51; p = 0.56).[65149]
For the treatment of community-acquired pneumonia (CAP)
Oral dosage (immediate-release)
• Outpatient Adults
500 mg PO on day 1, followed by 250 mg PO once daily for at least 5 days as monotherapy for patients without
comorbidities or risk factors for MRSA or P. aeruginosa and as part of combination therapy for patients with
comorbidities. Guide treatment duration by clinical stability.[28855] [34362] [64669] FDA-approved labeling
recommends a 5-day treatment course.[28855]
• Hospitalized Adults
500 mg PO once daily for at least 5 days as part of combination therapy. Guide treatment duration by clinical
stability.[34362] [64669]
• Adolescents
10 mg/kg/dose (Max: 500 mg/dose) PO for 1 day, followed by 5 mg/kg/dose (Max: 250 mg/dose) PO once daily 
for 4 days.[28855] Guidelines recommend azithromycin as oral step-down therapy or as initial oral therapy in 
patients with atypical pathogens and as part of combination therapy for HIV-infected patients.[34362] [46963]
• Infants and Children 6 months to 12 years
10 mg/kg/dose (Max: 500 mg/dose) PO for 1 day, followed by 5 mg/kg/dose (Max: 250 mg/dose) PO once daily
for 4 days.[28855] Guidelines recommend azithromycin as oral step-down therapy or as initial oral therapy in
patients with atypical pathogens and as part of combination therapy for hospitalized HIV-infected patients.
[34361] [46963]
• Infants 3 to 5 months†
10 mg/kg/dose PO for 1 day, followed by 5 mg/kg/dose PO once daily for 4 days. Guidelines recommend
azithromycin as oral step-down therapy or as initial oral therapy in patients with atypical pathogens and as part
of combination therapy for hospitalized HIV-infected patients.[34361] [46963]
Oral dosage (extended-release)
• Adults
2 g PO as a single dose. This dosage form is not recommended for patients with moderate or severe illness or
those with other underlying risk factors for which oral therapy is inappropriate.[34473]
• Infants, Children, and Adolescents 6 months to 17 years
60 mg/kg/dose (Max: 2 g/dose) PO as a single dose. This dosage form is not recommended for patients with
moderate or severe illness or those with other underlying risk factors for which oral therapy is inappropriate.
[34473]
Intravenous dosage
• Adults
500 mg IV once daily for at least 5 days as part of combination therapy for hospitalized patients. Guide
treatment duration by clinical stability.[34362] [64669] FDA-approved labeling recommends IV therapy for at least
2 days then step-down to oral therapy to complete a 7- to 10-day treatment course. The switch to oral therapy
should be done at the discretion of the physician and based on the clinical response of the patient.[43974]
• Adolescents 16 to 17 years
500 mg IV once daily for at least 2 days, followed by oral therapy to complete a 7- to 10-day treatment course.
[43974] Guidelines recommend azithromycin as monotherapy for definitive atypical pneumonia and as part of
combination therapy for hospitalized patients, including HIV-infected patients, when atypical pathogens are
suspected.[34362] [46963]
• Infants, Children, and Adolescents 3 months to 15 years†
10 mg/kg/dose (Max: 500 mg/dose) IV once daily for 2 days, followed by oral therapy to complete a 5-day
treatment course. Guidelines recommend azithromycin as monotherapy for definitive atypical pneumonia and as
part of combination therapy for hospitalized patients, including HIV-infected patients, when atypical pathogens
are suspected.[34361] [34362] [46963]
Therapeutic Drug Monitoring
The following recommendations are for baseline and continuous monitoring when using azithromycin with 
hydroxychloroquine or chloroquine:
• Obtain a pre-treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG device.
• Obtain baseline electrolytes, including calcium, magnesium, and potassium; correct abnormalities.
• Determine if the patient is currently on any QT-prolonging medications that can be discontinued.[65170]
• Document high-risk cardiovascular and comorbid conditions.[65170] Assess and adjust for hepatic and renal 
dysfunction.[65242]
Inpatient Use
• Place telemetry prior to initiation, if possible.
• Monitor and optimize serum electrolytes daily.[65242]
• If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an 
exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte abnormalities, 
review and discontinue other unnecessary QTc prolonging medications, and proceed with close QTc 
surveillance.[65170] Some experts recommend withholding treatment for patients with a baseline QTc of 
500 msec or more (or more than 530 to 550 msec in patients with a QRS interval more than 120 msec) or in 
those with congenital long QT syndrome.[65242]
• If the baseline QTc is 460 to 499 msec (prepubertal), 470 to 499 msec (postpubertal males), or 480 to 499 
msec (postpubertal females), correct contributing electrolyte abnormalities, review and discontinue other 
unnecessary QTc prolonging medications, and obtain an initial on-therapy QTc daily (or 48 and 96 hours 
after treatment initiation).[65170] [65242]
• If the baseline QTc is less than 460 msec (prepubertal), less than 470 msec (postpubertal males), or less than 
480 msec (postpubertal females), correct electrolyte abnormalities and obtain an initial on-therapy QTc 
daily (or 48 and 96 hours after treatment initiation).[65170] [65242]
• Obtain an initial on-therapy QTc approximately 2 to 4 hours after the first dose and then daily (some 
recommend 48 and 96 hours after treatment initiation).[65170] [65242]
• Discontinue azithromycin and/or reduce the antimalarial dose if the subsequent QTc is prolonged or 
significantly increased above the specified parameters. If the QTc remains prolonged or significantly 
increased, reevaluate the risk/benefit of therapy, consider consultation with an electrophysiologist, and 
consider hydroxychloroquine/chloroquine discontinuation.[65242]
Outpatient Use
• Do not initiate outpatient therapy in the setting of acute renal or hepatic failure.[65242]
• If the baseline QTc is 500 msec or more and/or the patient has an inherent tendency to develop an 
exaggerated QTc response (i.e., change of 60 msec or more), correct contributing electrolyte abnormalities, 
review and discontinue other unnecessary QTc prolonging medications, and proceed with close QTc 
surveillance.[65170] Some experts recommend withholding treatment in patients with a baseline QTc of 480 
msec or more (or more than 510 to 530 msec in patients with a QRS interval more than 120 msec), 
congenital long QT syndrome, or a Tisdale risk score of 11 or more.[65242]
• Consider no further ECG/telemetry assessment for patients with a Tisdale risk score of 6 or less, if resource 
or quarantine constraints are prohibitive of monitoring. Otherwise, repeat the ECT 2 to 3 hours after dosing 
on day 3 of therapy. If the QTc exceeds 500 msec (or 530 to 550 msec if QRS is more than 120 msec) or 
increases by more than 30 to 60 msec, consider discontinuing therapy.[65242]
Maximum Dosage Limits
• Adults 
500 mg/day PO is FDA-approved dosage; however, doses up to 1,200 mg/day PO are used off-label; 2 g PO 
when given as single dose; 500 mg/day IV infusion.
• Geriatric 
500 mg/day PO is FDA-approved dosage; however, doses up to 1,200 mg/day PO are used off-label; 2 g PO 
when given as single dose; 500 mg/day IV infusion.
• Adolescents 
16 to 17 years: 500 mg/day PO is FDA-approved dosage; however, doses up to 1,200 mg/day PO are used 
off-label; 2 g PO when given as single dose; 500 mg/day IV infusion.
13 to 15 years: For the immediate-release oral suspension or tablets, 12 mg/kg/day PO (Max: 500 mg/dose) 
and single doses up to 30 mg/kg PO (Max: 1.5 g/dose) are the maximum FDA-approved dosages; however, 
doses up to 20 mg/kg/day PO (Max: 1,000 mg/day) or 1,200 mg/day are used off-label. For extended-
release oral suspension, 60 mg/kg single dose PO (Max: 2 g/dose). Safety and efficacy have not been 
established for IV; however, doses up to 10 mg/kg/day (Max: 500 mg/dose) have been used off-label.
• Children 
2 to 12 years: For the immediate-release oral suspension or tablets, 12 mg/kg/day PO (Max: 500 mg/dose) 
and single doses up to 30 mg/kg PO (Max: 1.5 g/dose) are the maximum FDA-approved dosages; however, 
doses up to 20 mg/kg/day PO (Max: 1,000 mg/day) are used off-label. For extended-release oral 
suspension, 60 mg/kg single dose PO (Max: 2 g/dose). Safety and efficacy have not been established for IV; 
however, doses up to 10 mg/kg/day (Max: 500 mg/dose) have been used off-label.
1 year: For the immediate-release oral suspension or tablets, 10 mg/kg/day PO and single doses up to 30 
mg/kg PO are the maximum FDA-approved dosages; however, doses up to 20 mg/kg/day PO are used off-
label. For extended-release oral suspension, 60 mg/kg single dose PO. Safety and efficacy have not been 
established for IV; however, doses up to 10 mg/kg/day have been used off-label.
• Infants 
6 to 11 months: For the immediate-release oral suspension or tablets, 10 mg/kg/day PO and single doses up 
to 30 mg/kg PO are the maximum FDA-approved dosages; however, doses up to 20 mg/kg/day PO are used 
off-label. For extended-release oral suspension, 60 mg/kg single dose PO. Safety and efficacy have not been 
established for IV; however, doses up to 10 mg/kg/day have been used off-label.
3 to 5 months: Safety and efficacy have not been established; however, doses up to 20 mg/kg/day PO or 10 
mg/kg/day IV have been used off-label.
1 to 2 months: Safety and efficacy have not been established; however, doses up to 20 mg/kg/day PO have 
been used off-label.
• Neonates 
Safety and efficacy have not been established; however, doses up to 20 mg/kg/day PO have been used off-
label.
Patients with Hepatic Impairment Dosing
Dosage adjustment recommendations are not available; azithromycin has not been studied in patients with impaired 
hepatic function.[28855]
Patients with Renal Impairment Dosing
CrCl more than 80 mL/min: No dosage adjustment is needed.
CrCl 10 to 80 mL/min: No dosage adjustment is recommended.
CrCl less than 10 mL/min: No dosage adjustment is recommended; however, the manufacturer recommends caution in 
patients with severe renal impairment since mean AUC is increased roughly 35%.[28855][43974]
† Off-label indication
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How Supplied
Azithromycin Lyophilisate for solution for injection
Azithromycin 2.5g Powder for Injection (00703-9089) (Teva Pharmaceuticals USA) 
Azithromycin 500mg Powder for Injection (60505-6076) (Apotex Corp) 
Azithromycin 500mg Powder for Injection (70860-0100) (Athenex Pharmaceutical Division LLC) 
Azithromycin 500mg Powder for Injection (55150-0174) (AuroMedics Pharma LLC) 
Azithromycin 500mg Powder for Injection (10019-0648) (Baxter Anesthesia/Critical Care) (off market)
Azithromycin 500mg Powder for Injection (63323-0398) (Fresenius Kabi USA, LLC) 
Azithromycin 500mg Powder for Injection (10019-0648) (Hikma Pharmaceuticals USA inc.) (off market)
Azithromycin 500mg Powder for Injection (00409-0144) (Hospira Worldwide, Inc., a Pfizer Company) 
Azithromycin 500mg Powder for Injection (25021-0112) (Sagent Pharmaceuticals) (off market)
Azithromycin 500mg Powder for Injection (70436-0019) (Slate Run Pharmaceuticals, LLC) 
Azithromycin 500mg Powder for Injection (62756-0512) (Sun Pharmaceutical Industries, Inc.) 
Azithromycin 500mg Powder for Injection (00703-9085) (Teva Pharmaceuticals USA) (off market)
Azithromycin 500mg Powder for Injection (50111-0794) (Teva Pharmacueticals USA) 
Azithromycin 500mg Powder for Injection (NOVAPLUS) (70860-0125) (Athenex Pharmaceutical Division LLC) 
Azithromycin Lyophilisate for solution for injection
Azithromycin 500mg Powder for Injection (NOVAPLUS) (63323-0398) (Fresenius Kabi USA, LLC) 
Azithromycin 500mg Powder for Injection (PREMIER ProRx) (63323-0398) (Fresenius Kabi USA, LLC) 
Zithromax 500mg Powder for Injection (00069-3150) (Pfizer 
Inc.) 
Zithromax 500mg Powder for Injection (00069-3150) (Pfizer Inc.) (off market)
Zithromax 500mg Powder for Injection (Amerinet) (00069-0400) (Pfizer Injectables) 
Azithromycin Ophthalmic drops, solution
Azasite 1% Ophthalmic Solution (17478-0307) (Akorn Inc) 
Azasite 1% Ophthalmic Solution (31357-0040) (Inspire Pharmaceuticals 
Inc.) (off market)
Azasite 1% Ophthalmic Solution (31357-0040) (Inspire Pharmaceuticals 
Inc.) (off market)
Azasite 1% Ophthalmic Solution (31357-0040) (Oak Pharmaceuticals wholly-owned subsidiary Akorn Inc.) (off market)
Azithromycin Oral capsule
Zithromax 250mg Capsule (00069-3050) (Pfizer Inc.) (off market)
Zithromax Z-PAK 250mg Capsule (00069-6050) (Pfizer Inc.) (off market)
Azithromycin Oral tablet
Azithromycin 250mg Tablet (62332-0251) (Alembic Pharmaceuticals, Inc.) 
Azithromycin 250mg Tablet (68084-0278) (American Health Packaging) (off 
market)
Azithromycin 250mg Tablet (68084-0443) (American Health Packaging) 
Azithromycin 250mg Tablet (68084-0656) (American Health Packaging) (off 
market)
Azithromycin Oral tablet
Azithromycin 250mg Tablet (68084-0906) (American Health Packaging) (off 
market)
Azithromycin 250mg Tablet (68084-0278) (American Health Packaging) 
Azithromycin 250mg Tablet (60687-0282) (American Health Packaging) (off 
market)
Azithromycin 250mg Tablet (60687-0282) (American Health Packaging) 
Azithromycin 250mg Tablet (60505-2581) (Apotex Corp) 
Azithromycin 250mg Tablet (65862-0641) (Aurobindo Pharma USA Inc.) 
Azithromycin 250mg Tablet (50268-0098) (AvPAK; a Division of AvKARE Inc) (off market)
Azithromycin 250mg Tablet (50268-0100) (AvPAK; a Division of AvKARE Inc) (off 
market)
Azithromycin 250mg Tablet (50268-0103) (AvPAK; a Division of AvKARE Inc) (off market)
Azithromycin 250mg Tablet (50268-0098) (AvPAK; a Division of AvKARE Inc) 
Azithromycin 250mg Tablet (69452-0171) (Bionpharma Inc) 
Azithromycin 250mg Tablet (59762-3060) (Greenstone Ltd) 
Azithromycin 250mg Tablet (59762-2198) (Greenstone Ltd) 
Azithromycin 250mg Tablet (68180-0160) (Lupin Pharmaceuticals, Inc.) 
Azithromycin 250mg Tablet (00904-6010) (Major Pharmaceuticals Inc, a Harvard Drug Group Company) (off market)
Azithromycin 250mg Tablet (00904-6010) (Major Pharmaceuticals Inc, a Harvard Drug Group Company) (off market)
Azithromycin 250mg Tablet (00904-6405) (Major Pharmaceuticals Inc, a Harvard 
Drug Group Company) (off market)
Azithromycin Oral tablet
Azithromycin 250mg Tablet (00904-6708) (Major Pharmaceuticals Inc, a Harvard 
Drug Group Company) 
Azithromycin 250mg Tablet (63739-0575) (McKesson Packaging) (off market)
Azithromycin 250mg Tablet (51079-0591) (Mylan Institutional LLC ) 
Azithromycin 250mg Tablet (51079-0040) (Mylan Institutional LLC ) 
Azithromycin 250mg Tablet (43063-0090) (PD-Rx Pharmaceuticals, Inc.) (off market)
Azithromycin 250mg Tablet (55289-0964) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 250mg Tablet (43063-0090) (PD-Rx Pharmaceuticals, Inc.) (off market)
Azithromycin 250mg Tablet (43063-0524) (PD-Rx Pharmaceuticals, Inc.) (off 
market)
Azithromycin 250mg Tablet (43063-0572) (PD-Rx Pharmaceuticals, Inc.) (off 
market)
Azithromycin 250mg Tablet (43063-0728) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 250mg Tablet (33358-0040) (RxChange Co.) 
Azithromycin 250mg Tablet (00781-1496) (Sandoz Inc. a Novartis Company) (off 
market)
Azithromycin 250mg Tablet (00781-5776) (Sandoz Inc. a Novartis Company) 
Azithromycin Oral tablet
Azithromycin 250mg Tablet (00781-8089) (Sandoz Inc. a Novartis Company) 
Azithromycin 250mg Tablet (51224-0022) (TAGI Pharma, Inc.) 
Azithromycin 250mg Tablet (00093-7146) (Teva Pharmaceuticals USA) (off market)
Azithromycin 250mg Tablet (50111-0787) (Teva Pharmacueticals USA) (off market)
Azithromycin 250mg Tablet (50111-0787) (Teva Pharmacueticals USA) (off market)
Azithromycin 250mg Tablet (50111-0787) (Teva Pharmacueticals USA) 
Azithromycin 250mg Tablet (64679-0961) (Wockhardt USA, LLC) (off market)
Azithromycin 250mg Tablet (64679-0961) (Wockhardt USA, LLC) 
Azithromycin 250mg Tablet (6ct Blister Card) (60505-2581) (Apotex Corp) (off 
market)
Azithromycin 250mg Tablet (6ct Blister Card) (60505-2581) (Apotex Corp) 
Azithromycin 250mg Tablet (6ct Blister Card) (65862-0641) (Aurobindo Pharma USA Inc.) 
Azithromycin 250mg Tablet (6ct Blister Card) (70882-0107) (Cambridge 
Therapeutics Technologies, LLC) 
Azithromycin 250mg Tablet (6ct Blister Card) (59762-3060) (Greenstone Ltd) 
Azithromycin Oral tablet
Azithromycin 250mg Tablet (6ct Blister Card) (59762-2198) (Greenstone Ltd) 
Azithromycin 250mg Tablet (6ct Blister Card) (68180-0160) (Lupin 
Pharmaceuticals, Inc.) 
Azithromycin 250mg Tablet (6ct Blister Card) (00378-1533) (Mylan Pharmaceuticals Inc.) 
Azithromycin 250mg Tablet (6ct Blister Card) (00781-1496) (Sandoz Inc. a Novartis 
Company) (off market)
Azithromycin 250mg Tablet (6ct Blister Card) (00781-5776) (Sandoz Inc. a Novartis 
Company) (off market)
Azithromycin 250mg Tablet (6ct Blister Card) (00781-8089) (Sandoz Inc. a Novartis 
Company) 
Azithromycin 250mg Tablet (6ct Blister Card) (51224-0022) (TAGI Pharma, Inc.) 
Azithromycin 250mg Tablet (6ct Blister Card) (00093-7146) (Teva Pharmaceuticals 
USA) 
Azithromycin Oral tablet
Azithromycin 250mg Tablet (6ct Blister Card) (64679-0961) (Wockhardt USA, LLC) (off market)
Azithromycin 250mg Tablet (6ct Blister Card) (64679-0961) (Wockhardt USA, LLC) 
Zithromax 250mg Tablet (66267-0928) (NuCare Pharmaceuticals Inc) (off market)
Zithromax 250mg Tablet (55289-0310) (PD-Rx Pharmaceuticals, Inc.) 
Zithromax 250mg Tablet (58864-0791) (PD-Rx Pharmaceuticals, Inc.) (off market)
Zithromax 250mg Tablet (58864-0655) (PD-Rx Pharmaceuticals, Inc.) (off market)
Zithromax 250mg Tablet (00069-3060) (Pfizer Inc.) 
Zithromax 250mg Tablet (00069-4061) (Pfizer Inc.) 
Zithromax 250mg Tablet (00069-4061) (Pfizer Inc.) 
Zithromax Z-PAK 250mg Tablet (00069-3060) (Pfizer Inc.) 
Azithromycin 500mg Tablet (62332-0252) (Alembic Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (68084-0279) (American Health Packaging) (off 
market)
Azithromycin Oral tablet
Azithromycin 500mg Tablet (68084-0913) (American Health Packaging) (off 
market)
Azithromycin 500mg Tablet (68084-0279) (American Health Packaging) 
Azithromycin 500mg Tablet (60687-0271) (American Health Packaging) 
Azithromycin 500mg Tablet (60505-2582) (Apotex Corp) 
Azithromycin 500mg Tablet (65862-0642) (Aurobindo Pharma USA Inc.) 
Azithromycin 500mg Tablet (50268-0099) (AvPAK; a Division of AvKARE Inc) (off 
market)
Azithromycin 500mg Tablet (50268-0101) (AvPAK; a Division of AvKARE Inc) (off 
market)
Azithromycin 500mg Tablet (50268-0104) (AvPAK; a Division of AvKARE Inc) (off 
market)
Azithromycin 500mg Tablet (50268-0099) (AvPAK; a Division of AvKARE Inc) 
Azithromycin 500mg Tablet (69452-0172) (Bionpharma Inc) 
Azithromycin 500mg Tablet (70882-0108) (Cambridge Therapeutics Technologies, 
LLC) (off market)
Azithromycin Oral tablet
Azithromycin 500mg Tablet (59762-3070) (Greenstone Ltd) 
Azithromycin 500mg Tablet (68180-0161) (Lupin Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (00904-6011) (Major Pharmaceuticals Inc, a Harvard 
Drug Group Company) (off market)
Azithromycin 500mg Tablet (55289-0274) (PD-Rx Pharmaceuticals, Inc.) (off market)
Azithromycin 500mg Tablet (55289-0274) (PD-Rx Pharmaceuticals, Inc.) (off 
market)
Azithromycin 500mg Tablet (43063-0506) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (43063-0540) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (43063-0568) (PD-Rx Pharmaceuticals, Inc.) (off 
market)
Azithromycin 500mg Tablet (43063-0713) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (72789-0066) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (72789-0063) (PD-Rx Pharmaceuticals, Inc.) 
Azithromycin 500mg Tablet (00781-1941) (Sandoz Inc. a Novartis Company) (off 
market)
Azithromycin 500mg Tablet (00781-5789) (Sandoz Inc. a Novartis Company) 
Azithromycin Oral tablet
Azithromycin 500mg Tablet (51224-0122) (TAGI Pharma, Inc.) 
Azithromycin 500mg Tablet (00093-7169) (Teva Pharmaceuticals USA) 
Azithromycin 500mg Tablet (50111-0788) (Teva Pharmaceuticals USA) 
Azithromycin 500mg Tablet (50111-0788) (Teva Pharmacueticals USA) (off market)
Azithromycin 500mg Tablet (64679-0964) (Wockhardt USA, LLC) (off market)
Azithromycin 500mg Tablet (64679-0964) (Wockhardt USA, LLC) 
Azithromycin 500mg Tablet (3ct Blister Card) (60505-2582) (Apotex Corp) (off 
market)
Azithromycin 500mg Tablet (3ct Blister Card) (60505-2582) (Apotex Corp) 
Azithromycin 500mg Tablet (3ct Blister Card) (65862-0642) (Aurobindo Pharma USA Inc.) 
Azithromycin 500mg Tablet (3ct Blister Card) (70882-0118) (Cambridge 
Therapeutics Technologies, LLC) 
Azithromycin 500mg Tablet (3ct Blister Card) (59762-3070) (Greenstone Ltd) 
Azithromycin 500mg Tablet (3ct Blister Card) (68180-0161) (Lupin 
Pharmaceuticals, Inc.) 
Azithromycin Oral tablet
Azithromycin 500mg Tablet (3ct Blister Card) (00378-1534) (Mylan Pharmaceuticals Inc.) 
Azithromycin 500mg Tablet (3ct Blister Card) (55289-0274) (PD-Rx 
Pharmaceuticals, Inc.) (off market)
Azithromycin 500mg Tablet (3ct Blister Card) (00781-1941) (Sandoz Inc. a Novartis 
Company) (off market)
Azithromycin 500mg Tablet (3ct Blister Card) (00781-5789) (Sandoz Inc. a Novartis 
Company) (off market)
Azithromycin 500mg Tablet (3ct Blister Card) (00781-8090) (Sandoz Inc. a Novartis 
Company) 
Azithromycin 500mg Tablet (3ct Blister Card) (51224-0122) (TAGI Pharma, Inc.) 
Azithromycin 500mg Tablet (3ct Blister Card) (00093-7169) (Teva Pharmaceuticals 
USA) (off market)
Azithromycin 500mg Tablet (3ct Blister Card) (50111-0788) (Teva Pharmaceuticals 
USA) 
Azithromycin Oral tablet
Azithromycin 500mg Tablet (3ct Blister Card) (64679-0964) (Wockhardt USA, LLC) 
(off market)
Azithromycin 500mg Tablet (3ct Blister Card) (64679-0964) (Wockhardt USA, LLC) 
Zithromax 500mg Tablet (00069-3070) (Pfizer Inc.) 
Zithromax Tri-Pak 500mg Tablet (00069-3070) (Pfizer Inc.) 
Azithromycin 600mg Tablet (68084-0464) (American Health Packaging) 
Azithromycin 600mg Tablet (68084-0920) (American Health Packaging) (off market)
Azithromycin 600mg Tablet (60687-0314) (American Health Packaging) 
Azithromycin 600mg Tablet (60505-2583) (Apotex Corp) 
Azithromycin 600mg Tablet (69452-0173) (Bionpharma Inc) 
Azithromycin 600mg Tablet (59762-3080) (Greenstone Ltd) 
Azithromycin 600mg Tablet (68180-0162) (Lupin Pharmaceuticals, Inc.) 
Azithromycin 600mg Tablet (00378-1535) (Mylan Pharmaceuticals Inc.) 
Azithromycin 600mg Tablet (00781-1497) (Sandoz Inc. a Novartis Company) (off 
market)
Azithromycin Oral tablet
Azithromycin 600mg Tablet (00781-5793) (Sandoz Inc. a Novartis Company) 
Azithromycin 600mg Tablet (51224-0222) (TAGI Pharma, Inc.) 
Azithromycin 600mg Tablet (00093-7147) (Teva Pharmaceuticals USA) (off market)
Azithromycin 600mg Tablet (50111-0789) (Teva Pharmaceuticals USA) 
Azithromycin 600mg Tablet (50111-0789) (Teva Pharmacueticals USA) (off market)
Azithromycin 600mg Tablet (64679-0962) (Wockhardt USA, LLC) (off market)
Azithromycin 600mg Tablet (64679-0962) (Wockhardt USA, LLC) 
Zithromax 600mg Tablet (00069-3080) (Pfizer Inc.) 
Azithromycin Powder for oral suspension
Azithromycin 1g Single-Dose Powder for Suspension (59762-3051) 
(Greenstone Ltd) 
Zithromax 1g Single-Dose Powder for Suspension (00069-3051) (Pfizer Inc.) 
Azithromycin 100mg/5ml Powder for Suspension (59762-3110) (Greenstone 
Ltd) 
Azithromycin 100mg/5ml Powder for Suspension (00185-7203) (Sandoz Inc. a Novartis Company) 
Azithromycin 100mg/5ml Powder for Suspension (00093-7148) (Teva Pharmaceuticals USA) (off market)
Azithromycin 100mg/5ml Powder for Suspension (00093-2027) (Teva 
Pharmaceuticals USA) 
Azithromycin Powder for oral suspension
Azithromycin 100mg/5ml Powder for Suspension (00093-7148) (Teva Pharmaceuticals USA) (off market)
Azithromycin 100mg/5ml Powder for Suspension (50111-0793) (Teva 
Pharmacueticals USA) (off market)
Azithromycin 100mg/5mL Powder for Suspension (59651-0007) (Aurobindo Pharma Limited) 
Azithromycin 100mg/5mL Powder for Suspension (42806-0147) (Epic Pharma LLC) 
Azithromycin 100mg/5mL Powder for Suspension (43386-0470) (Gavis Pharmaceuticals, LLC, wholly owned subsidiary of Lupin) 
Azithromycin 100mg/5mL Powder for Suspension (70710-1457) (Zydus 
Pharmaceuticals (USA) Inc.) 
Zithromax 100mg/5mL Powder for Suspension (00069-3110) (Pfizer Inc.) 
Azithromycin 200mg/5ml Powder for Suspension (59762-3120) (Greenstone 
Ltd) 
Azithromycin 200mg/5ml Powder for Suspension (59762-3130) (Greenstone 
Ltd) 
Azithromycin 200mg/5ml Powder for Suspension (59762-3140) (Greenstone 
Ltd) 
Azithromycin 200mg/5ml Powder for Suspension (00185-7206) (Sandoz Inc. a Novartis Company) 
Azithromycin 200mg/5ml Powder for Suspension (00185-7209) (Sandoz Inc. a Novartis Company) 
Azithromycin 200mg/5ml Powder for Suspension (00185-7212) (Sandoz Inc. a Novartis Company) 
Azithromycin 200mg/5ml Powder for Suspension (00093-7149) (Teva Pharmaceuticals USA) (off market)
Azithromycin 200mg/5ml Powder for Suspension (00093-2026) (Teva 
Pharmaceuticals USA) 
Azithromycin Powder for oral suspension
Azithromycin 200mg/5ml Powder for Suspension (00093-7149) (Teva Pharmaceuticals USA) (off market)
Azithromycin 200mg/5ml Powder for Suspension (50111-0767) (Teva 
Pharmacueticals USA) (off market)
Azithromycin 200mg/5ml Powder for Suspension (50111-0791) (Teva 
Pharmacueticals USA) (off market)
Azithromycin 200mg/5ml Powder for Suspension (50111-0792) (Teva 
Pharmacueticals USA) (off market)
Azithromycin 200mg/5mL Powder for Suspension (59651-0008) (Aurobindo Pharma Limited) 
Azithromycin 200mg/5mL Powder for Suspension (42806-0149) (Epic Pharma LLC) 
Azithromycin 200mg/5mL Powder for Suspension (42806-0150) (Epic Pharma LLC) 
Azithromycin 200mg/5mL Powder for Suspension (42806-0151) (Epic Pharma LLC) 
Azithromycin 200mg/5mL Powder for Suspension (43386-0471) (Gavis Pharmaceuticals, LLC, wholly owned subsidiary of Lupin) 
Azithromycin 200mg/5mL Powder for Suspension (70710-1458) (Zydus 
Pharmaceuticals (USA) Inc.) 
Azithromycin 200mg/5mL Powder for Suspension (70710-1459) (Zydus 
Pharmaceuticals (USA) Inc.) 
Azithromycin 200mg/5mL Powder for Suspension (70710-1460) (Zydus 
Pharmaceuticals (USA) Inc.) 
Zithromax 200mg/5mL Powder for Suspension (00069-3130) (Pfizer Inc.) 
Zithromax 200mg/5mL Powder for Suspension (00069-3120) (Pfizer Inc.) 
Azithromycin Powder for oral suspension
Zithromax 200mg/5mL Powder for Suspension (00069-3140) (Pfizer Inc.) 
Azithromycin Powder for oral suspension, extended release
Zmax 2g Extended-Release Powder for Suspension (00069-4170) (Pfizer 
Inc.) (off market)
Zmax 2g Extended-Release Powder for Suspension (00069-4170) (Pfizer Inc.) 
Zmax Pediatric 2g Extended-Release Powder for Suspension (00069-4170) (Pfizer Inc.) (off market)
Description/Classification
Description
Azithromycin is a semisynthetic antibiotic belonging to the macrolide subgroup of azalides and is similar in structure 
to erythromycin. Azithromycin offers the advantage that it can be dosed once daily and produces less GI intolerance 
than does erythromycin. Azithromycin has a wider spectrum of activity than erythromycin against Mycobacterium 
avium complex (MAC), Haemophilus influenzae, nontuberculous mycobacteria, and Chlamydia trachomatis. Another 
apparent advantage over erythromycin is that azithromycin reaches higher intracellular concentrations, thus increasing 
its efficacy and duration of action.[50470] These advantages are demonstrated in studies that show that single doses of 
azithromycin are effective for the treatment of acute otitis media and sexually transmitted diseases (STDs) due to 
chlamydia and gonorrhea.[23529] [24204] [51748] Azithromycin is better tolerated and offers shorter treatment durations 
compared with clarithromycin.[50470] Azithromycin is used for the treatment of a variety of respiratory infections, 
including otitis media, pharyngitis/tonsillitis, pertussis, community-acquired pneumonia, and sinusitis.[28855] [51747]
However, macrolides are not recommended for empiric monotherapy of acute bacterial sinusitis due to high rates of 
Streptococcus pneumoniae resistance (approximately 30%).[49853] Azithromycin is also used for the treatment of STDs 
due to chlamydia and gonorrhea, and for the prophylaxis and treatment of Mycobacterium avium complex (MAC) 
disease.[34361] [43632] An ophthalmic preparation is used for the treatment of bacterial conjunctivitis.[43976] Long-term 
azithromycin is used off-label to improve lung function and decrease pulmonary exacerbation in cystic fibrosis patients 
6 years and older who have sputum cultures persistently positive for P. aeruginosa.[51770] Additionally, long-term 
azithromycin may be used as an add-on therapy in adults with moderate to severe asthma. Prior to starting therapy, 
sputum should be checked for atypical mycobacteria.[64807] While azithromycin has been studied in regimens for H. 
pylori eradication and some studies show efficacy, the azithromycin-containing regimens have not been as effective as 
regimens containing clarithromycin in terms of eradication rates.[51749] [51750] Macrolide cross-resistance is also an 
issue.[51751]
Updates for coronavirus disease 2019 (COVID-19):
Available data regarding the use of azithromycin as adjunctive treatment of COVID-19 due to SARS-CoV-2 are limited 
and inconclusive. Due to the potential for toxicities, the National Institutes of Health (NIH) COVID-19 treatment 
guidelines recommend against the use of azithromycin in combination with hydroxychloroquine outside of clinical 
trials.[65314] Azithromycin is being used in some COVID-19 protocols based on preliminary data; however, the risk of 
adverse events, particularly when given in combination with chloroquine or hydroxychloroquine (e.g., cardiac 
arrhythmias), should be considered. In an open-label, non-randomized clinical trial of hydroxychloroquine (n = 26), 
azithromycin was administered in combination with hydroxychloroquine to prevent bacterial superinfection in 6 
patients. On day 6, all patients treated with the combination (hydroxychloroquine and azithromycin) were virologically 
cured compared to 57.1% of patients treated with hydroxychloroquine alone (n= 20).[65147] Another small study (n = 
11) reviewed the same azithromycin plus hydroxychloroquine regimen and found nasopharyngeal swabs were still 
positive for SARS-CoV-2 in 8 of 10 patients 5 to 6 days after treatment initiation.[65198] In a retrospective analysis of a 
multicenter cohort study (n = 349) in patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), 136 
patients received macrolide therapy in combination with antiviral treatment. Macrolide therapy was not associated with 
a reduction in 90-day mortality compared to the control group.[65149]
Classifications
• General Anti-infectives Systemic
◦ Systemic Antibiotics
◾ Macrolide Antibiotics
• Sensory Organs
◦ Ophthalmologicals
◾ Ophthalmological Anti-infectives
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Oral Administration
Oral Solid Formulations
• May be taken with or without food; however, increased tolerability has been observed when the tablets are 
taken with food.[28855][43975]
Oral Liquid Formulations
Oral suspension (immediate-release, bottles for reconstitution):
• Review the reconstitution instructions for the particular product and package size, as the amount of water 
required for reconstitution may vary from manufacturer to manufacturer.
• Tap the bottle to loosen the powder. Add water in 2 portions and shake well after each portion.
• Azithromycin for oral suspension (100 mg/5 mL or 200 mg/5 mL strengths) may be taken with or without 
food.
• Measure dosage with a calibrated spoon, cup, or oral syringe.
• Storage after reconstitution: Store at 5 to 30 degrees C (41 to 86 degrees F). Discard any unused portion per 
manufacturer recommendations.[28855]
Oral suspension (1 gram single-dose packet):
• Do not use for administration of doses other than 1 gram.
• Zithromax for oral suspension (1-g single-dose packet) may be taken with or without food; however, 
administration with food may increase tolerability.
• Mix the entire contents of the packet in 60 mL (approximately 2 ounces) of water. Administer the entire 
contents immediately, then add an additional 60 mL of water, mix and administer to assure complete 
administration of the dosage.[43975]
Oral suspension (extended-release, bottles for reconstitution):
• Extended-release oral suspension (2 grams azithromycin) should be taken as a single dose at least 1 hour 
before or 2 hours after a meal.
• If a patient vomits within 5 minutes of the dose, the manufacturer recommends additional antibiotic 
treatment due to minimal absorption of the azithromycin dose. If a patient vomits between 5 to 60 minutes 
following the dose, consider alternate therapy. In patients with normal gastric emptying, if vomiting occurs 
60 minutes or later after the dose, no additional antibiotic therapy is warranted. In patients with delayed 
gastric emptying, consider alternative therapy.
• Constitute with 60 mL of water, replace cap, and shake bottle well.
• Storage after reconstitution: Do not refrigerate. Use within 12 hours.[34473]
Injectable Administration
• Visually inspect parenteral products for particulate matter and discoloration prior to administration 
whenever solution and container permit.
Intravenous Administration
Reconstitution:
NOTE: When using the Vial-Mate drug reconstitution device, please refer to the Vial-Mate instructions for assembly 
and reconstitution.[43974]
• Add 4.8 mL of Sterile Water Injection to a concentration of 100 mg/mL.
• Because the vial is supplied under vacuum, it is recommended that a standard 5 mL (non-automated) 
syringe be used to ensure that the exact amount of 4.8 mL of sterile water is dispensed.
• Shake until all of the drug is dissolved.
• Further dilution is required.
• Storage: The reconstituted solution is stable for 24 hours when stored below 30 degrees C (86 degrees F).
[43974]
Dilution:
• Dilute by transferring 5 mL of the reconstituted solution into a compatible diluent; use 500 mL of diluent 
for a concentration of 1 mg/mL and 250 mL of diluent for a concentration of 2 mg/mL.
• Compatible diluents include: 0.9% Sodium Chloride Injection, 0.45% Sodium Chloride Injection, 5% 
Dextrose Injection, Lactated Ringer's Injection, 5% Dextrose and 0.45% Sodium Chloride Injection with 20 
mEq KCl, 5% Dextrose and Lactated Ringer's Injection, 5% Dextrose and 0.3% Sodium Chloride Injection, 
5% Dextrose and 0.45% Sodium Chloride Injection, Normosol-M and 5% Dextrose Injection, and 
Normosol-R and 5% Dextrose Injection.
• Storage: Diluted solutions are stable for 24 hours at or below room temperature (30 degrees C or 86 degrees 
F) or for 7 days if stored under refrigeration (5 degrees C or 41 degrees F).[43974]
Intravenous infusion:
• Do not administer intramuscularly or via IV bolus.
• Other intravenous substances, additives, or medications should not be added to azithromycin or infused 
simultaneously through the same IV line.
• For a dose of 500 mg in 250 mL (concentration = 2 mg/mL), infuse over 1 hour. For a dose of 500 mg in 
500 mL (concentration = 1 mg/mL), infuse over 3 hours.[43974]
Ophthalmic Administration
• For ophthalmic use only. Apply topically only to the eye.
• Instruct patient on proper instillation of eye solution.
• Avoid contamination of the eye solution; do not touch the tip of the eye dropper to the eye, fingertips, or 
other surface.
• Due to the difficulty of administering eye drops to pediatric patients, consider a 2 person administration 
approach to ensure proper installation of the drops (1 person to hold the eyelids open and 1 person to 
administer the drops).
• To avoid contamination, do not share an opened bottle among patients.[43976]
Clinical Pharmaceutics Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Azithromycin
1. pH Range
pH 6.4 to 6.6
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2. Stability
Azithromycin injection in intact containers stored as directed by the manufacturer is stable until the labeled 
expiration date. The manufacturer indicates the reconstituted azithromycin injection is stable for 24 hours at 
controlled room temperature. Infusion Solutions: The manufacturer indicates that azithromycin diluted to 1 
to 2 mg/mL is stable for 24 hours at room temperature and 7 days refrigerated in the infusion solutions 
noted below. Dextrose 5% Dextrose 5% in lactated Ringer's Dextrose 5% in sodium chloride 0.3% Dextrose 
5% in sodium chloride 0.45% Dextrose 5% in sodium chloride 0.45% with potassium chloride 20 mEq/L 
Lactated Ringer's injection Normosol-M in dextrose 5% Normosol-R in dextrose 5% Sodium chloride 
0.45% Sodium chloride 0.9%
References
Anon. Manufacturer's information and labeling. (Package insert). 
3. pH Effects
Zhang et al. evaluated the stability of azithromycin in aqueous solution over a pH range of 4 to 7.2. They 
reported that azithromycin in aqueous solution exhibits maximum stability at pH 6.3. Below pH 6.0, the 
decomposition rate is rapid. At pH above 6.3 the rate of degradation increases with increasing pH. Mareno 
et al. similarly reported nearly total loss of azithromycin in hydrochloric acid and sodium hydroxide 
solutions with a concentration of 0.1 mol/L. Fiese et al. evaluated the stability of azithromycin in aqueous 
solution over the acidic pH range 1.0 to 4.1. Azithromycin underwent extensive decomposition at acidic pH. 
The time for 10% decomposition to occur at pH 2 was determined to be about 20 minutes at 37 degree C. 
The authors also reported that a ten-fold improvement in azithromycin stability occurred for each unit of pH 
increase within the tested range.
References
Fiese EF, Steffen SH. Comparison of acid stability of azithromycin and erythromycin A. J Antimicrob 
Chemother. 1990; 25sA:39-47 
Moreno AD, da Silva MFC, Salgado HRN. Stability studies of azithromycin in ophthalmic preparations. 
Braz J Pharm Sci. 2009; 45:219-26 
Zhang Y, Liu X, Cui Y, et al. Aspects of degradation kinetics of azithromycin in aqueous solution. 
Chromatographia. 2009; 70:67-73 
4. Light Exposure
Azithromycin in solution has been shown to undergo increased decomposition if exposed to sunlight and 
ultraviolet light.
References
Moreno AD, da Silva MFC, Salgado HRN. Stability studies of azithromycin in ophthalmic preparations. 
Braz J Pharm Sci. 2009; 45:219-26 
5. Other Information
Trace metals- Zhang et al. reported that the presence of EDTA does not alter the rate of azithromycin 
decomposition in solution indicating that trace metal ions are not likely to be involved in the degradation of 
azithromycin.
References
Zhang Y, Liu X, Cui Y, et al. Aspects of degradation kinetics of azithromycin in aqueous solution. 
Chromatographia. 2009; 70:67-73 
6. Stability Max
Maximum reported stability periods: Reconstituted solution- 24 hours at room temperature. In infusion 
solutions- 24 hours at room temperature and 7 days refrigerated
References
Anon. Manufacturer's information and labeling. (Package insert). 
Compounding Drug Information
From Trissel's 2™ Clinical Pharmaceutics Database 
Azithromycin
1. Identity/Properties
Azithromycin occurs as a white or almost white crystalline material. Solubility: Azithromycin is practically 
insoluble in water but freely soluble in dehydrated ethanol and dichloromethane. pH: Azithromycin oral 
suspension has a pH between 8.5 and 11. Reconstituted azithromycin injection at 100 mg/mL is buffered 
with citric acid to a pH of 6.4 to 6.6. pKa: Azithromycin has apparent pKa values of 9.16 and 9.37.
References
Anon. The Merck Index, Whitehouse Station, New Jersey: Merck & Co., Inc. Current edition. 
Anon. Martindale The Complete Drug Reference. London: The Pharmaceutical Press. Current edition and 
selected information from prior editions. 
Anon. The United States Pharmacopeia. Rockville, Maryland: The United States Pharmacopeial 
Convention. Current edition. 
Anon. Manufacturer's information and labeling. (Package insert and bulk material data sheet). 
Yuhas LM, Fuerst JK, Timpano JM, et al (Pfizer Laboratories, New York). Personal communication: pKa 
values of CP-62,993, azithromycin, assigned using 1H NMR spectroscopy. New York: Pfizer Laboratories; 
November 24, 2009. Data on file. 2009; :TriPharma 
2. General Stability Info
Azithromycin bulk powder and oral suspension powder should be packaged in tight containers and stored at 
controlled room temperature. Azithromycin oral capsules and tablets should be packaged in well-closed 
containers and stored at controlled room temperature. Single-dose packets of oral suspension powder should 
be stored between 5 and 30degree C. Azithromycin for injection vials should be stored at controlled room 
temperature. Reconstituted azithromycin oral suspension should be stored between 5 and 30degree C. After 
reconstitution, the oral suspension should be used according to the manufacturer's labeling for the specific 
product. Reconstituted azithromycin injection at 100 mg/mL is stable for 24 hours at controlled room 
temperature. Diluted for use to 1 to 2 mg/mL in a compatible infusion solution, the drug is stable for 24 
hours at controlled room temperature and for seven days refrigerated.
References
Anon. The United States Pharmacopeia. Rockville, Maryland: The United States Pharmacopeial 
Convention. Current edition. 
Anon. Manufacturer's information and labeling. (Package insert and bulk material data sheet). 
3. Enteral Feeds
Klang et al. evaluated the compatibility of azithromycin oral suspension 200 mg/5 mL with Osmolite 1.2 
(Abbott). Five milliliters of the drug was vortex mixed with 5 mL of the enteral nutrition product for one 
minute. The sample was placed in an incubated shaker at 37degree C for one hour. The mixture was 
evaluated for its ability to pass through a glass funnel stem (simulating a feeding tube). The portion of the 
mixture that passed through the funnel stem was filtered through a 100-micron filter and evaluated for 
retained solid matter. The test mixture passed through the glass funnel stem and did not demonstrate solid 
clumps upon filtration. Azithromycin oral suspension was reported to be compatible with Osmolite 1.2.
References
Klang M, McLymont V, Ng N. Osmolality, pH, and compatibility of selected oral liquid medications with 
an enteral product. J Parenter Enter Nutr. 2013; 37:689-94 
4. Rectal
Kauss et al. (2012) screened several compounded dosage forms of azithromycin for potential rectal 
administration in children who cannot take oral dosage forms. A rectal suspension, two rectal gels, a hard 
gelatin capsule, and a polyethylene glycol (PEG) suppository formulation were assessed; the suppository 
was selected as the best candidate dosage form for further development. Kauss et al. (2013) then developed 
and evaluated the stability of a pediatric PEG azithromycin rectal suppository formulation. Each 
suppository contained azithromycin 419 mg (equivalent to anhydrous azithromycin 400 mg), PEG 1500 
1760 mg, and PEG 4000 440 mg. The suppositories were prepared in three ways: as suspended, co-melted, 
and solid solution suppositories. The solid solution suppositories proved to be the preferred form. They 
were prepared by melting the PEGs at 90degree C using a water bath and then adding the azithromycin 
powder. The mixture was stirred until a homogenous limpid mixture was obtained. The mixture was cooled 
to 55 to 60degree C and was poured into 2-g suppository moulds. The suppositories were allowed to harden 
at room temperature in a dessicator for 24 hours. The stability of the solid solution azithromycin 
suppositories was evaluated at 40degree C and 75% relative humidity for 12 weeks packaged in alu/alu foil 
blisters (SGM India) and plastic moulds. In plastic moulds the suppositories underwent unacceptable 
changes including drug loss. However, in the alu/alu blisters the suppositories were much more stable. No 
change in the appearance and melting point of the suppositories occurred. HPLC analysis, differential 
scanning calorimetry, FTIR analysis, and X-ray diffraction found the azithromycin to be stable throughout 
the 12-week study period. In vitro drug release was unchanged, and in vivo bioavailability in rabbits was 
comparable to oral azithromycin.
References
Kauss T, Gaubert A, Boyer C, et al. Pharmaceutical development and optimization of azithromycin 
suppository for paediatric use. Int J Pharm. 2013; 441:218-26 
Kauss T, Gaubert A, Boyer C, et al. Screening paediatric rectal forms of azithromycin as an alternative to 
oral or injectable treatment. Int J Pharm. 2012; 436:624-30 
5. Ophthalmic
Ophthalmic preparations, like other sterile drugs, should be prepared in a suitable clean air environment 
using appropriate aseptic procedures. When prepared from non-sterile components, an appropriate and 
effective sterilization method must be employed. Mareno et al. evaluated factors that affect the stability of 
azithromycin ophthalmic solution. The ophthalmic solution had an azithromycin concentration of 1.667 
mg/mL in an unspecified physiological solution. The ophthalmic solution was subjected to a variety of 
stresses to observe the effects on the drug's stability. A microbiological assay technique was used to assess 
stability. Extremes of pH were evaluated using hydrochloric acid and sodium hydroxide 0.1 mol/L along 
with heat of 70degree C; these resulted in nearly total loss of the drug in six hours. Exposure to hydrogen 
peroxide 0.3% yielded a similar result. Exposure of the azithromycin ophthalmic solution to sunlight and 
ultraviolet light (at 254 and 284 nm) resulted in losses of 11, 38, and 20%, respectively, in 48 hours. The 
authors concluded that azithromycin ophthalmic solution pH and exposure to light should be controlled for 
stability.
References
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Adverse Reactions
• abdominal pain • acute generalized exanthematous pustulosis 
(AGEP)
• agitation
• anaphylactic shock
• anaphylactoid reactions
• anemia
• angioedema
• anorexia
• anosmia
• anxiety
• arthralgia
• asthenia
• atopic dermatitis
• azotemia
• blurred vision
• bronchospasm
• candidiasis
• chest pain (unspecified)
• chills
• cholestasis
• conjunctivitis
• constipation
• contact dermatitis
• corneal erosion
• cough
• diaphoresis
• diarrhea
• dizziness
• drowsiness
• Drug Reaction with Eosinophilia and Systemic 
Symptoms (DRESS)
• dysgeusia
• dysosmia
• dyspepsia
• dyspnea
• dysuria
• eczema vaccinatum
• edema
• elevated hepatic enzymes
• emotional lability
• eosinophilia
• erythema
• erythema multiforme
• fatigue
• fever
• flatulence
• gastritis
• headache
• hearing loss
• hepatic failure
• hepatic necrosis
• hepatitis
• hyperbilirubinemia
• hyperglycemia
• hyperkalemia
• hyperkinesis
• hypoglycemia
• hypokalemia
• hyponatremia
• hypotension
• injection site reaction
• insomnia
• interstitial nephritis
• irritability
• jaundice
• keratitis
• leukemia
• leukopenia
• lymphocytosis
• lymphoma
• lymphopenia
• maculopapular rash
• malaise
• melena
• myasthenia
• nasal congestion
• nausea
• neutropenia
• ocular discharge
• ocular irritation
• ocular pain
• ocular pruritus
• palpitations
• pancreatitis
• paresthesias
• pharyngitis
• photosensitivity
• pleural effusion
• pruritus
• pseudomembranous colitis
• pyloric stenosis
• QT prolongation
• rash
• renal failure (unspecified)
• rhinitis
• seizures
• sinusitis
• Stevens-Johnson syndrome
• stomatitis
• superinfection
• syncope
• thrombocytopenia
• tinnitus
• tongue discoloration
• torsade de pointes
• toxic epidermal necrolysis
• urticaria
• uveitis
• vaginitis
• ventricular tachycardia
• vertigo
• vesicular rash
• visual impairment
• vomiting
• xerophthalmia
The most common adverse reactions in patients receiving systemic regimens of azithromycin were gastrointestinal-
related, which tended to be more frequent in the single-dose oral regimens in adults and higher doses in pediatrics. 
Among the most commonly reported gastrointestinal adverse events were diarrhea or loose stools (4% to 14% of 
adults; 1.8% to 10% of pediatric patients), nausea (1.8% to 18% adults; 0.4% to 4% pediatrics), vomiting (up to 13% 
adults; 1.1% to 14% pediatrics), abdominal pain (1.9% to 14% adults; 1.2% to 4% pediatrics), flatulence (up to 5% 
adults; up to 1% pediatric patients), and anorexia (2% adults; up to 1% pediatrics). Adverse GI effects occurring in up 
to 1% of adult and pediatric patients included gastritis, constipation, and dyspepsia. In adults, melena, oral moniliasis, 
and mucositis were also reported in up to 1%; stomatitis was reported by 1.9% of adults. In pediatric patients, enteritis 
was reported in up to 1%. In HIV-infected patients receiving prophylactic azithromycin (i.e., 1,200 mg once weekly) 
for disseminated Mycobacterium avium complex (MAC) the incidences of the following GI-related adverse events 
were higher than other patient populations: diarrhea or loose stools (12.9% to 52.8%), nausea (27% to 32.6%), 
abdominal pain (27% to 32.2%), dyspepsia (4.7% to 9%), flatulence (9% to 10.7%), vomiting (6.7% to 9%), and 
anorexia 2.1%. Postmarketing adverse gastrointestinal reactions have also included pancreatitis and rare reports of 
tongue discoloration.[28855] [34473] [43974] [43975]
In clinical trials, elevated hepatic enzymes (ALT, AST) occurred in 4% to 6% of patients receiving intravenous 
azithromycin. Elevations of ALT (SGPT), GGT, and AST (SGOT) occurred with an incidence of 1% to 2% in patients 
receiving oral therapy. Hyperbilirubinemia was noted in up to 3% of patients. Up to 1% of drug recipients experienced 
cholestasis with jaundice. Postmarketing reports indicate that systemic azithromycin has been associated with 
abnormal liver function including cholestatic jaundice, hepatitis as well as rare cases of hepatic necrosis and hepatic 
failure, some of which have resulted in death.[28855] [34473] [43974] [43975]
Microbial overgrowth and superinfection can occur with antibiotic use. C. difficile-associated diarrhea (CDAD) or 
pseudomembranous colitis has been reported with azithromycin. If pseudomembranous colitis is suspected or 
confirmed, ongoing antibacterial therapy not directed against C. difficile may need to be discontinued. Institute 
appropriate fluid and electrolyte management, protein supplementation, C. difficile-directed antibacterial therapy, and 
surgical evaluation as clinically appropriate. Other infections reported during treatment with systemic azithromycin 
therapy during clinical trials included vaginitis (up to 2.8%), fungal superinfection (less than 1%), and fungal 
dermatitis (less than 1%). Cases of oral candidiasis (thrush) and vaginitis have also been noted during postmarketing 
use of the drug.[28855] [34473] [43974] [43975] [43976]
Hematologic adverse reactions noted in more than 1% of patients treated with systemic azithromycin during clinical 
trials included decreased hemoglobin, hematocrit, lymphocytes (lymphopenia), and neutrophils; as well as increased 
platelet counts, lymphocytes (lymphocytosis), neutrophils, and eosinophils (eosinophilia). Leukopenia, neutropenia, 
decreased platelet counts, elevated monocytes, and elevated basophils have been reported in less than 1% of adults. In 
children, anemia and leukopenia occurred in up to 1% of patients. Thrombocytopenia and mild neutropenia have been 
reported during postmarketing surveillance.[28855] [34473] [43974] [43975]
Respiratory adverse reactions have been reported in up to 1% of pediatric patients receiving azithromycin. These 
adverse reactions have included asthma, bronchitis, cough, pharyngitis, pleural effusion, and rhinitis. Dyspnea has been 
noted in 1.9% of patients receiving the intravenous formulation of azithromycin and in up to 1% of pediatric patients.
[28855] [34473] [43974] [43975] Nasal congestion and sinusitis have been reported in less than 1% of patients receiving 
the ophthalmic preparation of azithromycin.[43976]
An injection site reaction has been associated with the administration of intravenous azithromycin. Approximately 12% 
of patients treated for pneumonia experienced a side effect related to the intravenous infusion; most common were pain 
at the injection site (6.5%) and local inflammation or erythema (3.1%). Application site reactions occurred in 1.9% of 
patients receiving infusions for pelvic inflammatory disease.[43974]
During clinical trials, recipients of systemic azithromycin reported fatigue (up to 3.9%), fever (2.1%), malaise (up to 
1.1%), pain (up to 1%), chills and influenza-like symptoms (less than 1%), paresthesias (less than 1%), and asthenia
(less than 1%). Cases of asthenia, paresthesias, fatigue, and malaise have also been noted during postmarketing use of 
the drug.[28855] [34473] [43974] [43975]
Central nervous system (CNS) adverse reactions have been associated with the use of systemic azithromycin. In 
patients receiving systemic formulations of azithromycin during clinical trials, vertigo (up to 1%), headache (up to 
5%), dizziness (up to 3.9%), and somnolence or drowsiness (up to 1%) were reported. Additional CNS adverse 
reactions noted in less than 1% of pediatric drug recipients included agitation, nervousness, emotional lability, hostility, 
hyperkinesis, insomnia, and irritability. Postmarketing CNS effects have also included convulsions (seizures), 
hyperactivity, and syncope. Postmarketing psychiatric adverse reactions include aggression and anxiety.[28855] [34473]
[43974] [43975]
Cardiovascular adverse reactions associated with systemic azithromycin therapy reported in up to 1% of patients 
include chest pain (unspecified) and palpitations. Although uncommon, these are potentially serious adverse reactions. 
In postmarketing experience, there have been reports of arrhythmias including ventricular tachycardia, hypotension, 
QT prolongation, and torsade de pointes.[28855] [34473] [43974] [43975]
Conjunctivitis and uveitis were reported in up to 1% of patients receiving systemic azithromycin. Taste perversion 
(dysgeusia) was reported in up to 1.3% of patients receiving systemic azithromycin and in less than 1% of patients 
using the ophthalmic preparation. Decreased hearing (0.9% to 1.1%) and tinnitus (0.9% and 3.4%) were noted by 
patients receiving weekly azithromycin doses of 1,200 mg. During postmarketing use of systemic azithromycin, cases 
of dysgeusia, dysosmia (smell perversion) and anosmia (loss of smell), and hearing disturbances including hearing 
loss, deafness or tinnitus have been reported.[28855] [34473] [43974] [43975] [43976]
Dermatological and hypersensitivity-related adverse reactions have been reported with azithromycin therapy. During 
clinical trials, a generalized rash was reported in up to 8.1% of azithromycin recipients. More specifically, rashes were 
noted in 1% of adult patients receiving oral therapy, up to 5% of pediatric patients, 1.9% of patients receiving IV 
therapy, 3.4% to 8.1% of patients receiving a 1,200 mg once weekly dose, and in less than 1% of patients receiving 
ophthalmic therapy. Maculopapular rash and vesicular rash were reported in up to 1% of drug recipients. Patients also 
reported episodes of pruritus (up to 3.9%) and arthralgia (up to 3%). Other, less frequently reported adverse reactions 
(up to 1%) included photosensitivity, urticaria, bronchospasm, angioedema, and diaphoresis. Adverse events reported 
in less than 1% of patients using the ophthalmic solution included contact dermatitis, hives, and periocular swelling. 
Eczema vaccinatum (atopic dermatitis) was reported in up to 1% of pediatric patients, while dermatitis was noted in 
2% of pediatric patients. Cases of angioedema, arthralgia, edema, photosensitivity, pruritus, rash, and urticaria have 
also been noted during postmarketing use. Serious skin reactions including erythema multiforme, Stevens-Johnson 
syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been 
reported. Azithromycin therapy should be withdrawn if there are signs and symptoms of an allergic reaction. Some 
patients have a recurrence of allergic symptoms once symptomatic treatment is withdrawn, even though azithromycin 
therapy is not reinstated. Correlation between the long tissue half-life and duration of allergic symptoms has not yet 
been determined. Anaphylaxis (anaphylactoid reactions, anaphylactic shock) has been reported, including fatal cases.
[28855] [34473] [43974] [43975] [43976]
Systemic azithromycin therapy has been associated with cases of acute generalized exanthematous pustulosis (AGEP). 
The nonfollicular, pustular, erythematous rash starts suddenly and is associated with a fever above 38 degrees C. 
Typically, the first episode of AGEP appears 2 to 3 weeks after exposure to the inciting drug; however, unintentional 
reexposure may cause a second episode within 2 days.[27736] [43974]
Ocular irritation was the most frequently reported adverse reaction after ophthalmic administration of azithromycin and 
occurred in approximately 1% to 2% of patients. Other reported adverse reactions occurring in less than 1% of patients 
included blurred vision, corneal erosion, ocular discharge, ocular pain (burning, stinging, and irritation upon 
instillation), ocular pruritus, punctate keratitis, visual impairment (reduced visual acuity), and xerophthalmia.[43976]
The exacerbation of myasthenia gravis symptoms as well as the new onset of myasthenic syndrome have been reported 
with systemic azithromycin therapy. While rare, this side effect has been reported with other macrolide antibacterial 
agents.[28855] [34473] [43974] [43975]
Laboratory abnormalities have been noted with systemic azithromycin use. These include decreased bicarbonate (up to 
1%), increased bicarbonate (less than 1%), hyperkalemia (1% to 2%), hypokalemia (less than 1%), hyponatremia (less 
than 1%), hyperglycemia and hypoglycemia (up to 1%), elevated phosphokinase (1% to 2%), elevated serum alkaline 
phosphatase (less than 1%), elevated LDH (up to 3%), and elevated phosphate (less than 1%).[28855] [34473] [43974]
[43975]
An increased relapse rate of cancers of the blood or lymph nodes (i.e., leukemia, lymphoma), including death, has been 
observed in allogeneic stem cell transplant patients who were receiving azithromycin as prophylaxis for bronchiolitis 
obliterans syndrome (BOS). In a clinical trial (n = 480) evaluating the effectiveness of long-term azithromycin to 
prevent BOS in patients who undergo donor stem cell transplants for cancers of the blood or lymph nodes, cancer 
relapse was observed in 32.9% of azithromycin-treated patients vs. 20.8% of patients who were given a placebo. The 2-
year survival rate was 56.6% in azithromycin-treated patients vs. 70.1% in those given a placebo.[63410]
Renal adverse reactions in patients receiving systemic regimens of azithromycin included nephritis (up to 1% adults) 
and dysuria (up to 1% pediatric patients). Elevated BUN (azotemia) and elevated creatinine occurred in up to 1% of 
patients, with elevated creatinine reported in 4% to 6% of patients receiving IV therapy. Postmarketing adverse 
reactions have also included acute renal failure (unspecified) and interstitial nephritis.[28855] [34473] [43974] [43975]
Azithromycin has been associated with infantile hypertrophic pyloric stenosis (IHPS), particularly in newborns 
younger than 2 weeks of age. In a retrospective study of 148 infants given azithromycin during the first 14 days of life, 
IHPS developed in 3 patients (2%) for an odds ratio (OR) of 8.26 (95% CI: 2.62 to 26; p less than 0.001). Of 729 
infants aged 15 to 42 days at the time of azithromycin exposure, 5 patients developed IHPS for an OR of 2.98 (95% CI: 
1.24 to 7.2; p = 0.015). No infants aged 43 to 90 days at the time of azithromycin exposure developed IHPS. A male 
predominance was also observed, as all 8 infants who developed IHPS were boys. IHPS was also reported in 2 former 
32-week premature infants (2 out of 3 triplets) who received 5 days of azithromycin after hospitalization at 7 weeks of 
age. The infants were diagnosed with IHPS at 89 and 94 days of age, respectively, and both infants underwent surgical 
pyloromyotomies. Infants, particularly males who receive azithromycin within the first few weeks of life, should be 
closely monitored for signs and symptoms of IHPS for 6 weeks after azithromycin treatment. Pyloric stenosis rarely 
affects infants older than 3 months.[57925] [57926] Pyloric stenosis has been noted in postmarketing reports.[28855]
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Contraindications/Precautions
Absolute contraindications are italicized.
• hepatitis
• jaundice
• macrolide hypersensitivity
• allogeneic stem cell transplant 
• apheresis 
• AV block 
• bradycardia 
• breast-feeding 
• cardiomyopathy 
• celiac disease 
• contact lenses 
• diarrhea 
• females 
• fever 
• geriatric 
• heart failure 
• hepatic disease 
• human immunodeficiency virus (HIV) infection 
• hyperparathyroidism 
• hypocalcemia 
• hypokalemia 
• hypomagnesemia 
• hypothermia 
• hypothyroidism 
• infants 
• leukemia 
• long QT syndrome 
• lymphoma 
• myasthenia gravis 
• myocardial infarction 
• neonates 
• pheochromocytoma 
• pregnancy 
• pseudomembranous colitis 
• QT prolongation 
• renal failure 
• renal impairment 
• rheumatoid arthritis 
• serious hypersensitivity reactions or anaphylaxis 
• sexually transmitted disease 
• sickle cell disease 
• sleep deprivation 
• sodium restriction 
• stroke 
• sunlight (UV) exposure 
• systemic lupus erythematosus (SLE) 
• viral infection 
Azithromycin does not treat viral infection (e.g., common cold). Prescribing azithromycin in the absence of a proven or 
strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and 
increases the risk of the development of drug-resistant bacteria. Patients should be told to complete the full course of 
treatment, even if they feel better earlier.
Azithromycin is contraindicated in patients with a known azithromycin or macrolide hypersensitivity. Azithromycin 
has a rare risk of serious hypersensitivity reactions or anaphylaxis, including angioedema and severe dermatologic 
reactions, including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, and toxic 
epidermal necrolysis. Fatalities associated with these severe reactions have been reported. There is a risk of cross 
sensitivity with other macrolide antibiotics. Some patients have a recurrence of allergic symptoms once symptomatic 
treatment is withdrawn, even though azithromycin therapy is not reinstated.[28855] [43974]
Systemic azithromycin is contraindicated in patients with a history of jaundice and/or hepatic dysfunction associated 
with the prior use of azithromycin. Systemically administered azithromycin should be used with caution in patients 
who have hepatic disease. In addition, abnormal hepatic function, hepatitis, cholestatic jaundice, hepatic necrosis, and 
hepatic failure have been reported with use, including cases that have resulted in death. Monitor liver function tests in 
patients receiving systemic azithromycin. Discontinue treatment immediately if signs and symptoms of hepatitis and 
liver dysfunction occur.[28855]
Safe use of systemically-administered azithromycin in patients with severe renal impairment has not been determined; 
limited data are available. Azithromycin should be used cautiously in patients with preexisting severe renal impairment 
or renal failure (CrCl less than 10 ml/min).[28855]
Almost all antibacterial agents, including systemic azithromycin, have been associated with pseudomembranous colitis
or C. difficile-associated diarrhea (CDAD) which may range in severity from mild to life-threatening. Treatment with 
antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Consider 
pseudomembranous colitis in patients presenting with diarrhea after antibacterial use. Careful medical history is 
necessary as pseudomembranous colitis has been reported to occur over 2 months after the administration of 
antibacterial agents. If pseudomembranous colitis is suspected or confirmed, ongoing antibacterial therapy not directed 
against C. difficile may need to be discontinued. Institute appropriate fluid and electrolyte management, protein 
supplementation, C. difficile-directed antibacterial therapy, and surgical evaluation as clinically appropriate.[28855]
Macrolides are associated with QT prolongation; cases of cardiac arrhythmias and torsade de pointes (TdP) have been 
reported during postmarketing surveillance.[34473] Caution is warranted when using the drug in high-risk patients, 
including those with known prolongation of the QT interval or a history of TdP.[34473] Use azithromycin with caution 
in patients with conditions that may increase the risk of QT prolongation including congenital long QT syndrome, 
bradycardia, AV block, heart failure, stress-related cardiomyopathy, myocardial infarction, stroke, hypomagnesemia, 
hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval or cause electrolyte 
imbalances. Females, geriatric patients, patients with sleep deprivation, pheochromocytoma, sickle cell disease, 
hypothyroidism, hyperparathyroidism, hypothermia, systemic inflammation (e.g., human immunodeficiency virus 
(HIV) infection, fever, and some autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus 
(SLE), and celiac disease) and patients undergoing apheresis procedures (e.g., plasmapheresis [plasma exchange], 
cytapheresis) may also be at increased risk for QT prolongation.[28432] [28457] [43974] [56592] [65180] In patients taking 
azithromycin with another drug that prolongs the QT interval (see Therapeutic Drug Monitoring for recommendations 
specific to using azithromycin with chloroquine or hydroxychloroquine in the treatment of COVID-19), obtain a pre-
treatment QTc using a standard 12-lead ECG, telemetry, or mobile ECG device. Obtain baseline electrolytes, including 
calcium, magnesium, and potassium. Determine if the patient is currently on any QT-prolonging medications that can 
be discontinued. Document high-risk cardiovascular and comorbid conditions. If the baseline QTc is 500 msec or more 
and/or the patient has an inherent tendency to develop an exaggerated QTc response (i.e., change of 60 msec or more), 
correct contributing electrolyte abnormalities, review and discontinue other unnecessary QTc prolonging medications, 
and proceed with close QTc surveillance. Obtain an initial on-therapy QTc approximately 2 to 4 hours after the first 
dose and then again at 48 and 96 hours after treatment initiation. If the baseline QTc is 460 to 499 msec (prepubertal), 
470 to 499 msec (postpubertal males), or 480 to 499 msec (postpubertal females), correct contributing electrolyte 
abnormalities, review and discontinue other unnecessary QTc prolonging medications, and obtain an initial on-therapy 
QTc 48 and 96 hours after treatment initiation. If the baseline QTc is less than 460 msec (prepubertal), less than 470 
msec (postpubertal males), or less than 480 msec (postpuberal females), correct electrolyte abnormalities and obtain an 
initial on-therapy QTc 48 and 96 hours after treatment initiation.[65170] Data from a cohort study in adults have 
associated azithromycin with an increased risk of cardiovascular death. The study included persons receiving 
prescriptions for azithromycin (n = 347,795), amoxicillin (n = 1,348,672), ciprofloxacin (n = 264,626), levofloxacin (n 
= 193,906), and matched persons receiving no antibiotics (n = 1,391,180). Analysis of the data found those persons 
receiving a 5-day course of azithromycin had a significantly greater risk of cardiovascular death than persons not 
treated with antibiotics (HR: 2.88; 95% CI: 1.79 to 4.63; p less than 0.001), persons treated with 5 days of amoxicillin 
(HR: 2.49; 95% CI: 1.38 to 4.50; p = 0.002), and persons in the first 5 days of ciprofloxacin therapy (HR: 3.49; 95% 
CI: 1.32 to 9.26; p = 0.01); mortality rate did not differ from levofloxacin.[50182] [50183]
Clinical trials of oral and intravenous azithromycin and other reported clinical experience has not identified overall 
differences in safety and effectiveness between geriatric and younger adult subjects. Greater sensitivity of some older 
individuals cannot be ruled out. Health care providers are advised that geriatric patients may be more susceptible to 
drug-associated effects on the QT interval.[28855] [43974] The federal Omnibus Budget Reconciliation Act (OBRA) 
regulates medication use in residents of long-term care facilities. According to OBRA, use of antibiotics should be 
limited to confirmed or suspected bacterial infections. Antibiotics are non-selective and may result in the eradication of 
beneficial microorganisms while promoting the emergence of undesired ones, causing secondary infections such as 
oral thrush, colitis, or vaginitis. Any antibiotic may cause diarrhea, nausea, vomiting, anorexia, and hypersensitivity 
reactions.[60742]
Available data over several decades with systemic azithromycin use in pregnant women have not identified any drug-
associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Developmental toxicity 
studies in animals showed no drug-induced fetal malformations at doses up to 4 times the adult human daily dose of 
500 mg based on body surface area; however, decreased viability and delayed development were observed in the 
offspring of pregnant rats given azithromycin at a dose equivalent to 4 times the adult human daily dose from day 6 of 
pregnancy through weaning.[28855] In a nested, case-control study (n = 87,020 controls; 8,702 cases) within the 
Quebec Pregnancy Cohort, systemic azithromycin use during early pregnancy was associated with an increased risk of 
spontaneous abortion (adjusted odds ratio (aOR) 1.65, 95% CI 1.34 to 2.02, 110 exposed cases); residual confounding 
by severity of infection may be a potential limitation of this study.[62176] In a large population-based cohort study (n = 
104,605 live births) assessing systemic macrolide (n = 8,632) or penicillin (n = 95,973) use during pregnancy and the 
risk of major malformations, macrolide use in the first trimester was associated with increased risk of any 
malformation (27.7 vs. 17.7 per 1,000 live births; adjusted risk ratio 1.55, 95% CI 1.19 to 2.03), and in particular, 
cardiovascular malformations (10.6 vs. 6.6 per 1,000 live births; adjusted risk ratio 1.62, 95% CI 1.05 to 2.51). Specific 
findings for azithromycin use during the first trimester were precluded due to few events. Macrolide use during the 
second and third trimesters showed no increased risk of any major malformation (19.5 vs. 17.3 per 1,000 live births; 
adjusted risk ratio 1.13, 95% CI 0.94 to 1.36); however, a borderline association with gastrointestinal malformations 
was observed (adjusted risk ratio 1.89, 95% CI 1 to 3.58). Macrolide use in any trimester was associated with an 
increased risk of genital malformations (adjusted risk ratio 1.58, 95% CI 1.14 to 2.19), mainly hypospadias.[65012]
Additionally, in another large population-based cohort study (n = 139,938 live births) assessing systemic antibiotic 
exposure during the first trimester of pregnancy (n = 15,469 exposures) and the risk of major birth defects, macrolide 
exposure was associated with an increased risk of digestive system malformations (adjusted odds ratio (aOR) 1.46, 
95% CI 1.04 to 2.06, 35 exposed cases).[62177]
Azithromycin is present in human breast milk. Non-serious adverse reactions have been reported in breast-fed infants 
after maternal administration of azithromycin. Consider the developmental and health benefits of breast-feeding along 
with the mother's clinical need for azithromycin and any potential adverse effects on the breast-fed infant from 
azithromycin or the underlying maternal condition. Monitor the breast-fed infant for diarrhea, vomiting, or rash. There 
are no available data on the effects of azithromycin on milk production. Azithromycin breast milk concentrations were 
measured in 20 women receiving a single 2 g oral dose during labor. Azithromycin was present in breast milk up to 4 
weeks after dosing. Another study of 8 women receiving azithromycin IV before incision of cesarean section showed 
azithromycin was present in breast milk up to 48 hours later.[28855] A prospective observational study assessing the 
safety of macrolide antibiotics during lactation found that 12.7% (n = 55) of babies exposed to macrolides via breast 
milk experienced adverse events including rash, diarrhea, loss of appetite, and somnolence. The adverse event rate was 
similar to that seen in babies in a control group whose mothers were treated with amoxicillin (8.3%). Only 10 mothers 
in the study received azithromycin, 6 received clarithromycin, 2 received erythromycin, and the remainder were treated 
with roxythromycin.[45767] A population-based cohort study found that babies diagnosed with infantile hypertrophic 
pyloric stenosis were 2.3 to 3 times more likely to have been exposed to a macrolide antibiotic through breast milk 
during the first 90 days of life than babies not exposed during that same time period. The study did not specify which 
antibiotic the mothers of affected babies were prescribed; however, the majority of macrolide prescriptions were for 
erythromycin (72%), with 7% for azithromycin and 1.7% for clarithromycin.[45779] Previous American Academy of 
Pediatrics (AAP) recommendations consider erythromycin to be usually compatible with breast-feeding; azithromycin 
has not been evaluated by the AAP.[27500]
Use azithromycin with caution and with proper monitoring in young infants and neonates; there have been reports of 
infantile hypertrophic pyloric stenosis (IHPS) occurring in young infants after azithromycin therapy.[43974] [57925]
[57926] Because azithromycin is sometimes used for the treatment of conditions that are associated with significant 
mortality or morbidity (e.g., pertussis), weigh the benefit of azithromycin therapy against the potential risk of 
developing IHPS. Inform parents and other caregivers to contact their physician if vomiting or irritability with feeding 
occurs. In a retrospective study of 148 infants given azithromycin during the first 14 days of life, IHPS developed in 3 
patients (2%) for an odds ratio of 8.26 (95% CI: 2.62 to 26; p less than 0.001). Of 729 infants aged 15 to 42 days at the 
time of azithromycin exposure, 5 patients developed IHPS for an OR of 2.98 (95% CI: 1.24 to 7.2; p = 0.015). A male 
predominance was also observed, as all 8 infants who developed IHPS were boys. No infants aged 43 to 90 days at the 
time of azithromycin exposure developed IHPS; however, there have been 2 case reports of older infants developing 
IHPS (89 and 94 days old at diagnosis, respectively).[57925] [57926]
Direct sunlight (UV) exposure should be minimized during therapy with systemic azithromycin. Photosensitivity has 
been reported as an adverse reaction to azithromycin.[28855] [34473] [43975]
Some intravenous formulations of azithromycin contain a total of 4.96 mEq (114 mg) of sodium per 500-mg vial. The 
sodium amounts should be considered in patients with requirements for sodium restriction or blunted natriuresis to salt 
loading (i.e., cardiac disease or hypertension).[43974]
Patients who wear contact lenses should avoid wearing them while being treated for an ocular infection with 
azithromycin ophthalmic solution.[43976]
Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients 
receiving systemic azithromycin therapy.[28855]
While azithromycin may be used to treat certain sexually transmitted diseases (STD), the drug may mask or delay the 
symptoms of incubating syphilis when given as part of an STD treatment regimen. All patients with a diagnosed or 
suspected STD should be tested for other STDs, which may include HIV, syphilis, chlamydia, and gonorrhea, at the 
time of diagnosis. Initiate appropriate therapy and perform follow-up testing as recommended based upon sexually 
transmitted disease diagnosis.[28855] [59799]
Do not use azithromycin for long-term prophylaxis of bronchiolitis obliterans syndrome (BOS) in patients with cancers 
of the blood or lymph nodes (i.e. leukemia, lymphoma) who undergo an allogeneic stem cell transplant because of the 
increased risk for cancer relapse or death.[63410]
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Mechanism of Action
Azithromycin inhibits protein synthesis in bacterial cells by binding to the 50S subunit of bacterial ribosomes. Action 
is generally bacteriostatic but can be bactericidal in high concentrations or against susceptible organisms. Azithromycin 
is more active against gram-negative organisms but has less activity against streptococci and staphylococci than does 
erythromycin; erythromycin-resistant gram-positive isolates demonstrate cross-resistance to azithromycin.[34473]
[50470] Azithromycin concentrates in phagocytes and fibroblasts leading to high intracellular concentrations. Drug 
distribution to inflamed tissues is thought to occur from the concentration in phagocytes.[43975]
The susceptibility interpretive criteria for azithromycin are delineated by pathogen. The MICs are defined for beta-
hemolytic streptococci, S. viridans group, and S. pneumoniae as susceptible at 0.5 mcg/mL or less, intermediate at 1 
mcg/mL, and resistant at 2 mcg/mL or more. The MICs are defined for Staphylococcus sp. as susceptible at 2 mcg/mL 
or less, intermediate at 4 mcg/mL, and resistant at 8 mcg/mL or more. The MICs are defined for S. enterica ser. Typhi 
as susceptible at 16 mcg/mL or less and resistant at 32 mcg/mL or more. The MICs are defined for H. influenzae and 
H. parainfluenzae as susceptible at 4 mcg/mL or less. The MICs are defined for N. meningitidis as susceptible at 2 
mcg/mL or less, which may be only appropriate for prophylaxis of meningococcal case contacts and does not apply to 
treatment of invasive disease. The MICs are defined for N. gonorrhoeae as susceptible at 1 mcg/mL or less, presuming 
use of a 1 g single dose regimen that includes an additional antimicrobial agent.[63320] [63321]
Macrolides have been reported to have immunomodulatory properties in pulmonary inflammatory disorders. They may 
downregulate inflammatory responses and reduce the excessive cytokine production associated with respiratory viral 
infections; however, their direct effects on viral clearance are uncertain. Immunomodulatory mechanisms may include 
reducing chemotaxis of neutrophils (PMNs) to the lungs by inhibiting cytokines (i.e., IL-8), inhibition of mucus 
hypersecretion, decreased bacterial adhesion to the epithelium, decreased production of reactive oxygen species, 
accelerating neutrophil apoptosis, and blocking the activation of nuclear transcription factors.[65149] [65150] [65151]
[65152] [65153]
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Pharmacokinetics
Azithromycin is administered orally, intravenously, and topically to the eye. Following systemic administration, it is 
widely distributed to body tissues and fluids including bone, prostate, ovary, uterus, stomach, liver, middle ear, lung, 
tonsils and adenoids, and sputum.[28855][51754] Azithromycin exhibits significant intracellular penetration and 
concentrates within fibroblasts and phagocytes. As a result, tissue concentrations are significantly higher than are 
plasma concentrations.[34473][51757] Azithromycin is distributed widely into brain tissue but not into cerebrospinal 
fluid or the aqueous humor of the eye.[31755] Protein binding varies with plasma concentration; 51% of the drug is 
bound at low concentrations (0.02 mcg/ml) and this binding decreases to 7% at higher concentrations (2 mcg/ml).
[28855] Azithromycin has a long half-life in both adults (40 to 68 hours) and children (32 to 64 hours), which is 
partially explained by its extensive tissue uptake and slow release.[28855][43975][51754][51755][51756] Elimination is 
largely in the feces, following excretion into the bile, with less than 14% excreted in the urine.[28855][43974]
Affected cytochrome P450 isoenzymes and drug transporters: none
Route-Specific Pharmacokinetics
• Oral Route
Immediate-release suspension
Peak concentrations of azithromycin occur approximately 2 hours after administration.[51753] Food 
increases the Cmax by approximately 56%, but the extent of absorption is unaltered.[28855]
Single-dose (1 g) immediate-release suspension
Administration with food increased the Cmax by 46% and the AUC by 14%.[43975]
250 mg and 500 mg immediate-release tablets
The absolute bioavailability is approximately 38%. The Cmax for a 5-day regimen of 250 mg PO ranged 
from 0.24 to 0.43 mcg/mL and the AUC was 14.9 mcg x hour/mL. The Cmax for 3-day regimen of 500 mg 
PO ranged from 0.44 to 0.54 mcg/mL and the AUC was 17.4 mcg x hour/mL. Food increases the Cmax by 
approximately 23%, but the extent of absorption is unaltered.[28855]
600 mg immediate-release tablets
The absolute bioavailability is 34%. For a 1,200 mg dose, the Cmax is 0.33 mcg/mL, the Tmax is 2.5 hours, 
and the AUC is 6.8 mcg x hour/mL. Administration with food increased the Cmax by 31%; however, the 
AUC was unchanged.[43975]
Extended-release suspension
The bioavailability of the extended-release suspension compared to the immediate-release suspension is 
83%. Food increases absorption. Administration with a high-fat meal increased the Cmax by 115% and the 
AUC by 23% compared to the fasted state. Administration with a standard meal increased the Cmax by 
119% and the AUC by 12%.[34473] Peak concentrations occur approximately 3 hours (range 2 to 8 hours) 
after administration.[51753] Extended-release suspension and immediate-release formulations are not 
bioequivalent and cannot be interchanged.[34473]
• Intravenous Route
Azithromycin doses of 500 mg IV daily administered over 1 hour for 2 to 5 days resulted in a mean Cmax 
+/- SD of 3.63 +/- 1.60 mcg/mL, a 24-hour trough of 0.20 +/- 0.15 mcg/mL, and an AUC24 of 9.60 +/- 4.80 
mcg x hour/mL. Doses of 500 mg IV administered over 3 hours resulted in a mean Cmax of 1.14 +/- 0.14 
mcg/mL, a 24-hour trough of 0.18 +/- 0.02 mcg/mL, and an AUC24 of 8.03 +/- 0.86 mcg x hour/mL. 
Similar pharmacokinetic values were obtained in patients that received the same 3-hour IV infusion regimen 
for 2 to 5 days. A comparison of the pharmacokinetics after the first and fifth daily doses showed an 
increase in AUC24 of 61%, reflecting a 3-fold rise in trough concentrations. Cmax increased by 8%.[43974]
• Other Route(s)
Ophthalmic Route
The systemic concentration of azithromycin after ocular administration is estimated to be below 
quantifiable limits (10 ng/mL or less).[43976]
Special Populations
• Hepatic Impairment
Azithromycin pharmacokinetics have not been studied in patients with hepatic impairment. Azithromycin is 
not substantially metabolized.[28855]
• Renal Impairment
After the oral administration of a single 1,000 mg oral dose of azithromycin, mean Cmax was increased by 
5.1% and the AUC increased by 4.2% in subjects with mild to moderate renal impairment (GFR 10 to 80 
mL/minute) compared to subjects with normal renal function (GFR greater than 80 mL/minute). The Cmax 
and AUC of azithromycin are increased by 61% and 35%, respectively, in patients with severe renal 
impairment (GFR less than 10 mL/minute).[28855]
• Pediatrics
Immediate-release oral formulations:
Children and Adolescents 6 to 15 years
In a pharmacokinetic study in pediatric patients 6 years to 15 years who received 10 mg/kg azithromycin 
orally on day 1, followed by 5 mg/kg orally on days 2 to 5, mean Cmax, AUC, and clearance were 0.383 
mcg/mL, 3.109 mcg x hour/mL, and 4.27 L/kg/hour, respectively.[51756] [51760]
Infants and Children 6 months to 5 years
Maximum plasma concentrations (Cmax) and area under the curve (AUC) have been reported to be lower, 
and clearance has been reported to be higher for younger pediatric patients compared with older patients. In 
a pharmacokinetic study in pediatric patients 6 months to 5 years who received azithromycin 10 mg/kg 
orally on day 1, followed by 5 mg/kg orally on days 2 to 5, mean Cmax, AUC, and clearance were 0.224 
mcg/mL, 1.841 mcg x hour/mL, and 2.27 L/kg/hour, respectively. Mean elimination half-life was 32 hours.
[51755] [51756]
Extended-release suspension:
Infants, Children, and Adolescents 3 months to 16 years
The pharmacokinetics of azithromycin were characterized after a single 60 mg/kg dose in pediatric patients 
3 months to 16 years. Although there was high inter-patient variability in systemic exposure (AUC and 
Cmax) across the age groups studied, individual azithromycin AUC and Cmax values in pediatric patients 
were comparable to or higher than those after administration of 2 g extended-release suspension in adults.
[34473]
Intravenous formulation: 
Infants, Children, and Adolescents 6 months to 15 years
In a pharmacokinetic study in pediatric patients (6 months to less than 16 years), after a single azithromycin 
IV dose of 10 mg/kg (Max: 500 mg/dose), mean peak concentration was 2.4 mcg/mL, clearance was 15.3 
mL/minute/kg, and elimination half-life was 65 hours. Peak concentrations occurred 1 hour after 
administration. No differences in pharmacokinetic parameters were noted among different age groups.
[31756]
• Geriatric
The pharmacokinetic parameters of azithromycin in older volunteers (65 to 85 years) were similar to those 
in younger volunteers for a 5-day oral regimen.[28855]
• Gender Differences
No significant differences in azithromycin pharmacokinetics occur based on gender.[28855]
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Pregnancy/Breast-feeding
Pregnancy
Available data over several decades with systemic azithromycin use in pregnant women have not identified any drug-
associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Developmental toxicity 
studies in animals showed no drug-induced fetal malformations at doses up to 4 times the adult human daily dose of 
500 mg based on body surface area; however, decreased viability and delayed development were observed in the 
offspring of pregnant rats given azithromycin at a dose equivalent to 4 times the adult human daily dose from day 6 of 
pregnancy through weaning.[28855] In a nested, case-control study (n = 87,020 controls; 8,702 cases) within the 
Quebec Pregnancy Cohort, systemic azithromycin use during early pregnancy was associated with an increased risk of 
spontaneous abortion (adjusted odds ratio (aOR) 1.65, 95% CI 1.34 to 2.02, 110 exposed cases); residual confounding 
by severity of infection may be a potential limitation of this study.[62176] In a large population-based cohort study (n = 
104,605 live births) assessing systemic macrolide (n = 8,632) or penicillin (n = 95,973) use during pregnancy and the 
risk of major malformations, macrolide use in the first trimester was associated with increased risk of any 
malformation (27.7 vs. 17.7 per 1,000 live births; adjusted risk ratio 1.55, 95% CI 1.19 to 2.03), and in particular, 
cardiovascular malformations (10.6 vs. 6.6 per 1,000 live births; adjusted risk ratio 1.62, 95% CI 1.05 to 2.51). Specific 
findings for azithromycin use during the first trimester were precluded due to few events. Macrolide use during the 
second and third trimesters showed no increased risk of any major malformation (19.5 vs. 17.3 per 1,000 live births; 
adjusted risk ratio 1.13, 95% CI 0.94 to 1.36); however, a borderline association with gastrointestinal malformations 
was observed (adjusted risk ratio 1.89, 95% CI 1 to 3.58). Macrolide use in any trimester was associated with an 
increased risk of genital malformations (adjusted risk ratio 1.58, 95% CI 1.14 to 2.19), mainly hypospadias.[65012]
Additionally, in another large population-based cohort study (n = 139,938 live births) assessing systemic antibiotic 
exposure during the first trimester of pregnancy (n = 15,469 exposures) and the risk of major birth defects, macrolide 
exposure was associated with an increased risk of digestive system malformations (adjusted odds ratio (aOR) 1.46, 
95% CI 1.04 to 2.06, 35 exposed cases).[62177]
Breast-Feeding
Azithromycin is present in human breast milk. Non-serious adverse reactions have been reported in breast-fed infants 
after maternal administration of azithromycin. Consider the developmental and health benefits of breast-feeding along 
with the mother's clinical need for azithromycin and any potential adverse effects on the breast-fed infant from 
azithromycin or the underlying maternal condition. Monitor the breast-fed infant for diarrhea, vomiting, or rash. There 
are no available data on the effects of azithromycin on milk production. Azithromycin breast milk concentrations were 
measured in 20 women receiving a single 2 g oral dose during labor. Azithromycin was present in breast milk up to 4 
weeks after dosing. Another study of 8 women receiving azithromycin IV before incision of cesarean section showed 
azithromycin was present in breast milk up to 48 hours later.[28855] A prospective observational study assessing the 
safety of macrolide antibiotics during lactation found that 12.7% (n = 55) of babies exposed to macrolides via breast 
milk experienced adverse events including rash, diarrhea, loss of appetite, and somnolence. The adverse event rate was 
similar to that seen in babies in a control group whose mothers were treated with amoxicillin (8.3%). Only 10 mothers 
in the study received azithromycin, 6 received clarithromycin, 2 received erythromycin, and the remainder were treated 
with roxythromycin.[45767] A population-based cohort study found that babies diagnosed with infantile hypertrophic 
pyloric stenosis were 2.3 to 3 times more likely to have been exposed to a macrolide antibiotic through breast milk 
during the first 90 days of life than babies not exposed during that same time period. The study did not specify which 
antibiotic the mothers of affected babies were prescribed; however, the majority of macrolide prescriptions were for 
erythromycin (72%), with 7% for azithromycin and 1.7% for clarithromycin.[45779] Previous American Academy of 
Pediatrics (AAP) recommendations consider erythromycin to be usually compatible with breast-feeding; azithromycin 
has not been evaluated by the AAP.[27500]
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Interactions
Level 1 (Severe)
• Cisapride
• Dronedarone
• Pimozide
• Thioridazine
Level 2 (Major)
• Aclidinium; Formoterol
• Albuterol
• Albuterol; Ipratropium
• Alfuzosin
• Amiodarone
• Amitriptyline
• Amitriptyline; Chlordiazepoxide
• Anagrelide
• Apomorphine
• Arformoterol
• Aripiprazole
• Arsenic Trioxide
• Artemether; Lumefantrine
• Asenapine
• Atomoxetine
• Bedaquiline
• Bismuth Subcitrate Potassium; Metronidazole; 
Tetracycline
• Bismuth Subsalicylate; Metronidazole; 
Tetracycline
• Budesonide; Formoterol
• Buprenorphine
• Buprenorphine; Naloxone
• Ceritinib
• Chloroquine
• Chlorpromazine
• Ciprofloxacin
• Citalopram
• Clofazimine
• Clomipramine
• Clozapine
• Codeine; Phenylephrine; Promethazine
• Codeine; Promethazine
• Crizotinib
• Dasatinib
• Degarelix
• Desflurane
• Desipramine
• Deutetrabenazine
• Dextromethorphan; Promethazine
• Dextromethorphan; Quinidine
• Disopyramide
• Dofetilide
• Dolasetron
• Dolutegravir; Rilpivirine
• Donepezil
• Donepezil; Memantine
• Doxepin
• Droperidol
• Efavirenz
• Efavirenz; Emtricitabine; Tenofovir
• Efavirenz; Lamivudine; Tenofovir Disoproxil 
Fumarate
• Eliglustat
• Emtricitabine; Rilpivirine; Tenofovir alafenamide
• Emtricitabine; Rilpivirine; Tenofovir disoproxil 
fumarate
• Encorafenib
• Enflurane
• Entrectinib
• Eribulin
• Escitalopram
• Ezogabine
• Fingolimod
• Flecainide
• Fluconazole
• Fluoxetine
• Fluoxetine; Olanzapine
• Fluphenazine
• Fluticasone; Salmeterol
• Fluticasone; Umeclidinium; Vilanterol
• Fluticasone; Vilanterol
• Fluvoxamine
• Formoterol
• Formoterol; Mometasone
• Foscarnet
• Gemifloxacin
• Gemtuzumab Ozogamicin
• Gilteritinib
• Glasdegib
• Glycopyrrolate; Formoterol
• Goserelin
• Granisetron
• Halogenated Anesthetics
• Haloperidol
• Halothane
• Histrelin
• Hydroxychloroquine
• Hydroxyzine
• Ibutilide
• Iloperidone
• Imipramine
• Indacaterol
• Indacaterol; Glycopyrrolate
• Inotuzumab Ozogamicin
• Isoflurane
• Itraconazole
• Ivosidenib
• Ketoconazole
• Lapatinib
• Lefamulin
• Lenvatinib
• Leuprolide
• Leuprolide; Norethindrone
• Levalbuterol
• Levofloxacin
• Lithium
• Lofexidine
• Long-acting beta-agonists
• Loperamide
• Loperamide; Simethicone
• Lopinavir; Ritonavir
• Macimorelin
• Maprotiline
• Mefloquine
• Meperidine; Promethazine
• Metaproterenol
• Methadone
• Metronidazole
• Midostaurin
• Mifepristone
• Mirtazapine
• Moxifloxacin
• Nilotinib
• Nortriptyline
• Octreotide
• Ofloxacin
• Olanzapine
• Olodaterol
• Ondansetron
• Osilodrostat
• Osimertinib
• Oxaliplatin
• Paliperidone
• Panobinostat
• Pasireotide
• Pazopanib
• Pentamidine
• Perphenazine
• Perphenazine; Amitriptyline
• Phenylephrine; Promethazine
• Pimavanserin
• Pirbuterol
• Pitolisant
• Posaconazole
• Primaquine
• Procainamide
• Prochlorperazine
• Promethazine
• Propafenone
• Protriptyline
• Quetiapine
• Quinidine
• Quinine
• Ranolazine
• Ribociclib
• Ribociclib; Letrozole
• Rilpivirine
• Risperidone
• Romidepsin
• Salmeterol
• Saquinavir
• Sertraline
• Sevoflurane
• Short-acting beta-agonists
• Siponimod
• Sodium picosulfate; Magnesium oxide; Anhydrous 
citric acid
• Solifenacin
• Sorafenib
• Sotalol
• Sunitinib
• Tacrolimus
• Tamoxifen
• Telavancin
• Telithromycin
• Terbutaline
• Tetrabenazine
• Tiotropium; Olodaterol
• Tolterodine
• Toremifene
• Trazodone
• Tricyclic antidepressants
• Trifluoperazine
• Trimipramine
• Triptorelin
• Umeclidinium; Vilanterol
• Vandetanib
• Vardenafil
• Vemurafenib
• Venlafaxine
• Voriconazole
• Vorinostat
• Ziprasidone
Level 3 (Moderate)
• Aluminum Hydroxide
• Aluminum Hydroxide; Magnesium Carbonate
• Aluminum Hydroxide; Magnesium Hydroxide
• Aluminum Hydroxide; Magnesium Hydroxide; 
Simethicone
• Aluminum Hydroxide; Magnesium Trisilicate
• Aspirin, ASA; Pravastatin
• Calcium Carbonate; Magnesium Hydroxide
• Colchicine
• Colchicine; Probenecid
• Conjugated Estrogens; Bazedoxifene
• Cyclosporine
• Dienogest; Estradiol valerate
• Digoxin
• Drospirenone
• Drospirenone; Estradiol
• Drospirenone; Ethinyl Estradiol
• Drospirenone; Ethinyl Estradiol; Levomefolate
• Estradiol; Levonorgestrel
• Estradiol; Norethindrone
• Estradiol; Norgestimate
• Ethinyl Estradiol
• Ethinyl Estradiol; Desogestrel
• Ethinyl Estradiol; Ethynodiol Diacetate
• Ethinyl Estradiol; Etonogestrel
• Ethinyl Estradiol; Levonorgestrel
• Ethinyl Estradiol; Levonorgestrel; Ferrous 
bisglycinate
• Ethinyl Estradiol; Levonorgestrel; Folic Acid; 
Levomefolate
• Ethinyl Estradiol; Norelgestromin
• Ethinyl Estradiol; Norethindrone
• Ethinyl Estradiol; Norethindrone Acetate
• Ethinyl Estradiol; Norethindrone Acetate; Ferrous 
fumarate
• Ethinyl Estradiol; Norethindrone; Ferrous 
fumarate
• Ethinyl Estradiol; Norgestimate
• Ethinyl Estradiol; Norgestrel
• Levonorgestrel
• Magnesium Hydroxide
• Mestranol; Norethindrone
• Nelfinavir
• Norethindrone
• Norgestrel
• Oral Contraceptives
• Pravastatin
• Segesterone Acetate; Ethinyl Estradiol
• Talazoparib
• Warfarin
Level 4 (Minor)
• Belladonna Alkaloids; Ergotamine; Phenobarbital
• Caffeine; Ergotamine
• Dihydroergotamine
• Ergotamine
• Fosphenytoin
• Phenytoin
Aclidinium; Formoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Albuterol: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Albuterol; Ipratropium: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Alfuzosin: (Major) Avoid coadministration of azithromycin with alfuzosin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Alfuzosin may prolong the QT interval in a dose-dependent manner. [28261] [28855] [43974]
[65157] [65170]
Aluminum Hydroxide: (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral 
absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be 
taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken 
without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]
Aluminum Hydroxide; Magnesium Carbonate: (Moderate) Antacids containing aluminum salts and/or magnesium salts 
can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If 
antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension 
may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473]
[43975]
Aluminum Hydroxide; Magnesium Hydroxide: (Moderate) Antacids containing aluminum salts and/or magnesium 
salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma 
concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-
release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum 
hydroxide. [28855] [34473] [43975]
Aluminum Hydroxide; Magnesium Hydroxide; Simethicone: (Moderate) Antacids containing aluminum salts and/or 
magnesium salts can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma 
concentrations. If antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-
release suspension may be taken without regard to antacids containing magnesium hydroxide and/or aluminum 
hydroxide. [28855] [34473] [43975]
Aluminum Hydroxide; Magnesium Trisilicate: (Moderate) Antacids containing aluminum salts and/or magnesium salts 
can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If 
antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension 
may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473]
[43975]
Amiodarone: (Major) Avoid coadministration of amiodarone and azithromycin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Amiodarone, a Class III antiarrhythmic agent, is associated with a well-established risk of QT 
prolongation and torsade de pointes (TdP). Although the frequency of TdP is less with amiodarone than with other 
Class III agents, amiodarone is still associated with a risk of TdP. Due to the extremely long half-life of amiodarone, a 
drug interaction is possible for days to weeks after discontinuation of amiodarone. Reports of QT prolongation and 
torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. QT 
prolongation was reported in a 68-year old woman receiving azithromycin and amiodarone. The patient had a history 
of stable congestive heart failure and a posterior communicating artery aneurysm. She was receiving amiodarone (200 
mg/day) for over a year for paroxysmal atrial fibrillation. Additional medications included furosemide, enalapril, and 
aspirin. A regular sinus rhythm with normal P-R, QRST, and QTc intervals was noted prior to initiation of azithromycin 
therapy. Therapy with azithromycin was started at 500 mg PO on day 1, followed by 250 mg PO once daily for 4 days. 
Sinus bradycardia with marked QT prolongation and increased QT dispersion were noted on day 3 of treatment. 
Azithromycin was discontinued; QT and QTc intervals and QT dispersion returned to baseline in 4 days. Hypokalemia 
or hypomagnesemia were not noted in the patient and the amiodarone dose remained consistent at 200 mg/day. [28224]
[28432] [28457] [28855] [43974] [65157] [65170]
Amitriptyline: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Amitriptyline; Chlordiazepoxide: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants 
(TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging 
drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously 
reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA 
antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription 
therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Anagrelide: (Major) Avoid coadministration of azithromycin with anagrelide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. TdP and ventricular tachycardia have been reported with anagrelide. In addition, dose-
related increases in mean QTc and heart rate were observed in healthy subjects. [28855] [30163] [43974] [65157] [65170]
Apomorphine: (Major) Avoid coadministration of azithromycin with apomorphine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Limited data indicate that QT prolongation is also possible with apomorphine 
administration; the change in QTc interval is not significant in most patients receiving dosages within the 
manufacturer's guidelines. [28661] [28855] [43974] [65157] [65170]
Arformoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]
Aripiprazole: (Major) Avoid coadministration of azithromycin with aripiprazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation has occurred during therapeutic use of aripiprazole and following 
overdose. [28855] [42845] [43974] [65157] [65170]
Arsenic Trioxide: (Major) Avoid coadministration of azithromycin with arsenic trioxide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. TdP, QT interval prolongation, and complete atrioventricular block have been reported 
with arsenic trioxide use. [28226] [28855] [43974] [65157] [65170]
Artemether; Lumefantrine: (Major) Avoid coadministration of azithromycin with artemether; lumefantrine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Artemether; lumefantrine is associated with prolongation of the QT interval. 
[28432] [28855] [35401] [43974] [65157] [65170]
Asenapine: (Major) Avoid coadministration of azithromycin with asenapine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Asenapine has been associated with QT prolongation. [28432] [28855] [36343] [43974]
[65157] [65170]
Aspirin, ASA; Pravastatin: (Moderate) Azithromycin has the potential to increase pravastatin exposure when used 
concomitantly. Coadminister pravastatin and azithromycin cautiously due to a potential increased risk of myopathies. 
[45507]
Atomoxetine: (Major) Avoid coadministration of azithromycin with atomoxetine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation has occurred during therapeutic use of atomoxetine and following 
overdose. [28405] [28855] [43974] [59321] [65157] [65170]
Bedaquiline: (Major) Avoid coadministration of azithromycin with bedaquiline due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Discontinue bedaquiline if evidence of serious ventricular arrhythmia or QTcF interval greater than 500 
ms. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Bedaquiline prolongs the QT interval. [28855] [34329] [43974] [52746] [65157] [65170]
Belladonna Alkaloids; Ergotamine; Phenobarbital: (Minor) Carefully monitor patients when azithromycin and 
ergotamine are used concomitantly. Pharmacokinetic and/or pharmacodynamic interactions with ergotamine have been 
observed with other macrolides. [28858] [34473]
Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: (Major) Avoid coadministration of azithromycin with 
metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been 
spontaneously reported during azithromycin postmarketing surveillance. Potential QT prolongation has been reported 
in limited case reports with metronidazole. [28855] [43974] [57377] [57378] [65157] [65170]
Bismuth Subsalicylate; Metronidazole; Tetracycline: (Major) Avoid coadministration of azithromycin with 
metronidazole due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been 
spontaneously reported during azithromycin postmarketing surveillance. Potential QT prolongation has been reported 
in limited case reports with metronidazole. [28855] [43974] [57377] [57378] [65157] [65170]
Budesonide; Formoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Buprenorphine: (Major) Avoid coadministration of azithromycin with buprenorphine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. 
[28855] [41235] [43974] [60270] [65157] [65170]
Buprenorphine; Naloxone: (Major) Avoid coadministration of azithromycin with buprenorphine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Buprenorphine has been associated with QT prolongation and has a possible 
risk of TdP. [28855] [41235] [43974] [60270] [65157] [65170]
Caffeine; Ergotamine: (Minor) Carefully monitor patients when azithromycin and ergotamine are used concomitantly. 
Pharmacokinetic and/or pharmacodynamic interactions with ergotamine have been observed with other macrolides. 
[28858] [34473]
Calcium Carbonate; Magnesium Hydroxide: (Moderate) Antacids containing aluminum salts and/or magnesium salts 
can decrease the oral absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If 
antacids must be taken, stagger the administration of the antacid and azithromycin. The extended-release suspension 
may be taken without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473]
[43975]
Ceritinib: (Major) Avoid coadministration of azithromycin with ceritinib if possible due to the risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An 
interruption of ceritinib therapy, dose reduction, or discontinuation of therapy may be necessary if QT prolongation 
occurs. Ceritinib causes concentration-dependent QT prolongation. QT prolongation and torsade de pointes (TdP) have 
been spontaneously reported during azithromycin postmarketing surveillance. [28225] [43974] [57094] [65157] [65170]
Chloroquine: (Major) Avoid coadministration of chloroquine with azithromycin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances (See Therapeutic Drug Monitoring for recommendations specific to COVID-19). Chloroquine is associated 
with an increased risk of QT prolongation and torsade de pointes (TdP); the risk of QT prolongation is increased with 
higher chloroquine doses. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. [28229] [28230] [28231] [28855] [29758] [43974] [65157] [65170]
Chlorpromazine: (Major) Avoid coadministration of azithromycin with chlorpromazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Chlorpromazine is associated with an established risk of QT prolongation and TdP. [28415]
[28416] [28417] [28855] [43065] [43974] [65157] [65170]
Ciprofloxacin: (Major) Avoid coadministration of azithromycin with ciprofloxacin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Rare cases of QT prolongation and TdP have been reported with ciprofloxacin during 
postmarketing surveillance. [28432] [28457] [28855] [29833] [33144] [33145] [33146] [43411] [43974] [48869] [48871] [65157]
[65170]
Cisapride: (Severe) There have been case reports of QT prolongation and torsade de pointes (TdP) with the use of 
azithromycin in post-marketing reports. Azithromycin is contraindicated with other drugs that have been specifically 
established that have a causal association with QT prolongation and torsade de pointes, such as cisapride. [28407]
[28855] [43974]
Citalopram: (Major) Avoid coadministration of azithromycin with citalopram due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Citalopram causes dose-dependent QT interval prolongation. [28269] [28855] [43974] [65157]
[65170]
Clofazimine: (Major) Avoid coadministration of azithromycin with clofazimine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation and TdP have been reported in patients receiving clofazimine in 
combination with QT prolonging medications. [28855] [43974] [63936] [65157] [65170]
Clomipramine: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Clozapine: (Major) Avoid coadministration of azithromycin with clozapine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Treatment with clozapine has been associated with QT prolongation, TdP, cardiac arrest, 
and sudden death. [28262] [28855] [43974] [65157] [65170]
Codeine; Phenylephrine; Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225]
[28855] [43974] [55578] [65157] [65170]
Codeine; Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974]
[55578] [65157] [65170]
Colchicine: (Moderate) Caution is warranted with the concomitant use of colchicine and azithromycin as increased 
colchicine concentrations may occur. Monitor for colchicine toxicity. Colchicine accumulation may be greater in 
patients with renal or hepatic impairment. Coadministration with azithromycin resulted in an increase in colchicine 
Cmax of 21.6% and an increase in the AUC of 57.1%. [36114]
Colchicine; Probenecid: (Moderate) Caution is warranted with the concomitant use of colchicine and azithromycin as 
increased colchicine concentrations may occur. Monitor for colchicine toxicity. Colchicine accumulation may be 
greater in patients with renal or hepatic impairment. Coadministration with azithromycin resulted in an increase in 
colchicine Cmax of 21.6% and an increase in the AUC of 57.1%. [36114]
Conjugated Estrogens; Bazedoxifene: (Moderate) Coadministration of azithromycin and bazedoxifene increased the 
Cmax of bazedoxifene by 6% and decreased AUC of bazedoxifene by 15%. The clinical effect of these changes is not 
described. [56074]
Crizotinib: (Major) Avoid coadministration of crizotinib with azithromycin due to the risk of QT prolongation. If use 
together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of subsequent 
ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. An interruption of 
therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib if QT prolongation occurs. 
Crizotinib has been associated with concentration-dependent QT prolongation. Prolongation of the QT interval and 
torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28855]
[43974] [45458] [65157] [65170]
Cyclosporine: (Moderate) Caution is warranted with the concomitant use of azithromycin and cyclosporine as 
increased cyclosporine concentrations may occur. Dose adjustment of cyclosporine may be necessary; monitor 
cyclosporine serum concentrations during use with azithromycin and after discontinuation of azithromycin. [28404]
Dasatinib: (Major) Avoid coadministration of azithromycin with dasatinib due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. In vitro studies have shown that dasatinib has the potential to prolong cardiac ventricular repolarization 
(prolong QT interval). [28855] [32387] [43974] [65157] [65170]
Degarelix: (Major) Avoid coadministration of azithromycin with degarelix due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Androgen deprivation therapy (i.e., degarelix) may prolong the QT/QTc interval. [28855]
[43974] [46869] [65157] [65170]
Desflurane: (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]
Desipramine: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Deutetrabenazine: (Major) Avoid coadministration of azithromycin with deutetrabenazine due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. For patients taking a deutetrabenazine dosage more than 24 mg/day with azithromycin, assess the QTc 
interval before and after increasing the dosage of either medication. QT prolongation and torsade de pointes (TdP) have 
been spontaneously reported during azithromycin postmarketing surveillance. Clinically relevant QTc prolongation 
may occur with deutetrabenazine. [28855] [43974] [61845] [65157] [65170]
Dextromethorphan; Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225]
[28855] [43974] [55578] [65157] [65170]
Dextromethorphan; Quinidine: (Major) Avoid coadministration of azithromycin with quinidine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Quinidine administration is associated with QT prolongation and TdP. [28855]
[42280] [43974] [47357] [65157] [65170]
Dienogest; Estradiol valerate: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Digoxin: (Moderate) Monitor digoxin concentrations before and during concomitant use of azithromycin and reduce 
the digoxin dose if necessary. Elevated digoxin concentrations have been observed when azithromycin has been 
coadministered with digoxin. [28272] [29743]
Dihydroergotamine: (Minor) Carefully monitor patients when azithromycin and dihydroergotamine are used 
concomitantly. Pharmacokinetic and/or pharmacodynamic interactions with dihydroergotamine have been observed 
with other macrolides. [28858] [34473]
Disopyramide: (Major) Avoid coadministration of azithromycin with disopyramide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Disopyramide is associated with QT prolongation and TdP. [28228] [28855] [43974] [65157]
[65170]
Dofetilide: (Major) Avoid coadministration of azithromycin with dofetilide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Dofetilide, a Class III antiarrhythmic agent, is associated with a well-established risk of 
QT prolongation and TdP. [28221] [28432] [28457] [28855] [43974] [65157] [65170]
Dolasetron: (Major) Avoid coadministration of azithromycin with dolasetron due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Dolasetron has been associated with a dose-dependent prolongation in the QT, PR, and 
QRS intervals on an electrocardiogram. [28855] [42844] [43974] [65157] [65170]
Dolutegravir; Rilpivirine: (Major) Avoid coadministration of azithromycin with rilpivirine due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. 
[28855] [43974] [44376] [65157] [65170]
Donepezil: (Major) Avoid coadministration of azithromycin with donepezil due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy. 
[28855] [43974] [59321] [59322] [65157] [65170]
Donepezil; Memantine: (Major) Avoid coadministration of azithromycin with donepezil due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Case reports indicate that QT prolongation and TdP can occur during donepezil therapy. 
[28855] [43974] [59321] [59322] [65157] [65170]
Doxepin: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Dronedarone: (Severe) Coadministration of dronedarone and azithromycin is contraindicated due to the potential for 
QT prolongation and torsade de pointes (TdP). There have been case reports of QT prolongation and TdP with the use 
of azithromycin in post-marketing reports. Dronedarone administration is associated with a dose-related increase in the 
QTc interval. The increase in QTc is approximately 10 milliseconds at doses of 400 mg twice daily (the FDA-approved 
dose) and up to 25 milliseconds at doses of 1600 mg twice daily. Although there are no studies examining the effects of 
dronedarone in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT 
prolongation. [28855] [36101] [43974]
Droperidol: (Major) Avoid coadministration of azithromycin with droperidol due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Initiate droperidol at a low dose and increase the dose as needed to achieve the desired effect. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Droperidol administration is associated with an established risk for QT prolongation and TdP. Some cases 
have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal. [28235]
[28236] [28237] [28855] [43974] [51289] [65157] [65170]
Drospirenone: (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Drospirenone; Estradiol: (Moderate) It would be prudent to recommend alternative or additional contraception when 
oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Drospirenone; Ethinyl Estradiol: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Drospirenone; Ethinyl Estradiol; Levomefolate: (Moderate) It would be prudent to recommend alternative or additional 
contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that 
antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction 
in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Efavirenz: (Major) Avoid coadministration of azithromycin with efavirenz due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QTc prolongation has been observed with the use of efavirenz. [28442] [28855] [43974]
[65157] [65170]
Efavirenz; Emtricitabine; Tenofovir: (Major) Avoid coadministration of azithromycin with efavirenz due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. QTc prolongation has been observed with the use of efavirenz. [28442]
[28855] [43974] [65157] [65170]
Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of azithromycin with 
efavirenz due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess 
initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging 
drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously 
reported during azithromycin postmarketing surveillance. QTc prolongation has been observed with the use of 
efavirenz. [28442] [28855] [43974] [65157] [65170]
Eliglustat: (Major) Avoid coadministration of azithromycin with eliglustat due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Eliglustat is predicted to cause PR, QRS, and/or QT prolongation at significantly elevated plasma 
concentrations. [28855] [43974] [57803] [65157] [65170]
Emtricitabine; Rilpivirine; Tenofovir alafenamide: (Major) Avoid coadministration of azithromycin with rilpivirine due 
to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and 
correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT 
prolongation. [28855] [43974] [44376] [65157] [65170]
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: (Major) Avoid coadministration of azithromycin with 
rilpivirine due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to 
assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been 
spontaneously reported during azithromycin postmarketing surveillance. Supratherapeutic doses of rilpivirine (75 to 
300 mg/day) have caused QT prolongation. [28855] [43974] [44376] [65157] [65170]
Encorafenib: (Major) Avoid coadministration of azithromycin with encorafenib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. Encorafenib is associated with dose-dependent prolongation of the QT interval. QT prolongation and 
torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing surveillance. [28855]
[43974] [61570] [63317] [65157]
Enflurane: (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]
Entrectinib: (Major) Avoid coadministration of azithromycin with entrectinib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Entrectinib has been associated with QT prolongation. [28855] [43974] [64567] [65157]
[65170]
Ergotamine: (Minor) Carefully monitor patients when azithromycin and ergotamine are used concomitantly. 
Pharmacokinetic and/or pharmacodynamic interactions with ergotamine have been observed with other macrolides. 
[28858] [34473]
Eribulin: (Major) Avoid coadministration of azithromycin with eribulin due to the increased risk of QT prolongation. If 
use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Eribulin has been associated with QT prolongation. [28855] [42449] [43974] [65157] [65170]
Escitalopram: (Major) Avoid coadministration of azithromycin with escitalopram due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Escitalopram has been associated with a risk of QT prolongation and TdP. [28270] [28855]
[43974] [65157] [65170]
Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when 
oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Estradiol; Norethindrone: (Moderate) It would be prudent to recommend alternative or additional contraception when 
oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Estradiol; Norgestimate: (Moderate) It would be prudent to recommend alternative or additional contraception when 
oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol: (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Desogestrel: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Ethynodiol Diacetate: (Moderate) It would be prudent to recommend alternative or additional 
contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that 
antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction 
in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Etonogestrel: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional 
contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that 
antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction 
in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Levonorgestrel; Ferrous bisglycinate: (Moderate) It would be prudent to recommend alternative or 
additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously 
thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism 
or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to 
determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also 
examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded 
that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Levonorgestrel; Folic Acid; Levomefolate: (Moderate) It would be prudent to recommend alternative 
or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously 
thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism 
or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to 
determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also 
examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded 
that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norelgestromin: (Moderate) It would be prudent to recommend alternative or additional 
contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that 
antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction 
in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norethindrone Acetate: (Moderate) It would be prudent to recommend alternative or additional 
contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that 
antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction 
in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: (Moderate) It would be prudent to recommend alternative 
or additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously 
thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism 
or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to 
determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also 
examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded 
that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norethindrone: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norethindrone; Ferrous fumarate: (Moderate) It would be prudent to recommend alternative or 
additional contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously 
thought that antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism 
or a reduction in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to 
determine the effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also 
examined clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded 
that the antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norgestimate: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ethinyl Estradiol; Norgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception 
when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Ezogabine: (Major) Avoid coadministration of azithromycin with ezogabine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Ezogabine has been associated with QT prolongation. [28855] [43974] [44800] [65157]
[65170]
Fingolimod: (Major) Avoid coadministration of azithromycin with fingolimod due to the increased risk of QT 
prolongation. If concomitant use is unavoidable, overnight monitoring with continuous ECG in a medical facility is 
advised after the first dose of fingolimod; monitor ECG closely throughout therapy, avoid any non-essential QT 
prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been 
spontaneously reported during azithromycin postmarketing surveillance. Fingolimod initiation results in decreased 
heart rate and may prolong the QT interval. Fingolimod has not been studied in patients treated with drugs that prolong 
the QT interval, but drugs that prolong the QT interval have been associated with cases of TdP in patients with 
bradycardia. [28855] [41823] [43974] [65157] [65170]
Flecainide: (Major) Avoid coadministration of azithromycin with flecainide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Flecainide is a Class IC antiarrhythmic and is also associated with a possible risk for QT 
prolongation and/or TdP; flecainide increases the QT interval, but largely due to prolongation of the QRS interval. 
Although causality for TdP has not been established for flecainide, patients receiving concurrent drugs which have the 
potential for QT prolongation, such as azithromycin, may have an increased risk of developing proarrhythmias. [23774]
[28752] [28855] [43974] [65157] [65170]
Fluconazole: (Major) Avoid coadministration of azithromycin with fluconazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Fluconazole has been associated with QT prolongation and rare cases of TdP. [28674]
[28855] [43974] [65157] [65170]
Fluoxetine: (Major) Avoid coadministration of azithromycin with fluoxetine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation and TdP have been reported in patients treated with fluoxetine. [28855]
[32127] [43974] [65157] [65170]
Fluoxetine; Olanzapine: (Major) Avoid coadministration of azithromycin with fluoxetine due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation and TdP have been reported in patients treated with fluoxetine. [28855]
[32127] [43974] [65157] [65170] (Major) Avoid coadministration of azithromycin with olanzapine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Limited data, including some case reports, suggest that olanzapine may be 
associated with a significant prolongation of the QTc interval. [28785] [28855] [32732] [32734] [32745] [32746] [43974]
[65157] [65170]
Fluphenazine: (Major) Avoid coadministration of azithromycin with fluphenazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Fluphenazine is associated with a possible risk for QT prolongation. Theoretically, 
fluphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT 
prolongation. [28514] [28855] [43974] [65157] [65170]
Fluticasone; Salmeterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Fluticasone; Umeclidinium; Vilanterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists 
due to the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and 
correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Fluticasone; Vilanterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Fluvoxamine: (Major) Avoid coadministration of azithromycin with fluvoxamine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation and TdP have been reported during fluvoxamine postmarketing use. 
[28855] [50507] [65157] [65170]
Formoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]
Formoterol; Mometasone: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Foscarnet: (Major) Avoid coadministration of azithromycin with foscarnet due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Both QT prolongation and TdP have been reported during postmarketing use of foscarnet. 
[28377] [28855] [43974] [65157] [65170]
Fosphenytoin: (Minor) Until more data are available, the manufacturer of azithromycin recommends caution and 
careful monitoring of patients who receive azithromycin with fosphenytoin. Azithromycin was not implicated in 
clinical trials with drug interactions with fosphenytoin. However, specific drug interaction studies have not been 
performed with the combination of azithromycin and fosphenytoin. [28855]
Gemifloxacin: (Major) Avoid coadministration of azithromycin with gemifloxacin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Gemifloxacin may also prolong the QT interval in some patients. The maximal change in 
the QTc interval occurs approximately 5 to 10 hours following oral administration of gemifloxacin. The likelihood of 
QTc prolongation may increase with increasing dose of the drug; therefore, the recommended dose should not be 
exceeded especially in patients with renal or hepatic impairment where the Cmax and AUC are slightly higher. [28419]
[28420] [28424] [28855] [43974] [65157] [65170]
Gemtuzumab Ozogamicin: (Major) Avoid coadministration of azithromycin with gemtuzumab due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Although QT interval prolongation has not been reported with gemtuzumab, it has been 
reported with other drugs that contain calicheamicin. [28855] [43974] [62292] [65157] [65170]
Gilteritinib: (Major) Avoid coadministration of azithromycin with gilteritinib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Gilteritinib has been associated with QT prolongation. [28855] [43974] [63787] [65157]
[65170]
Glasdegib: (Major) Avoid coadministration of azithromycin with glasdegib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Glasdegib therapy may result in QT prolongation and ventricular arrhythmias including 
ventricular fibrillation and ventricular tachycardia. [28855] [43974] [63777] [65157] [65170]
Glycopyrrolate; Formoterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Goserelin: (Major) Avoid coadministration of azithromycin with goserelin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28592] [28855] [43974]
[65157] [65170]
Granisetron: (Major) Avoid coadministration of azithromycin with granisetron due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Granisetron has been associated with QT prolongation. [28855] [31723] [43974] [65157]
[65170]
Halogenated Anesthetics: (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974]
[65157] [65170]
Haloperidol: (Major) Avoid coadministration of azithromycin with haloperidol due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Excessive doses (particularly in the overdose setting) or IV administration of haloperidol 
may be associated with a higher risk of QT prolongation. [23500] [23779] [28225] [28307] [28415] [28416] [28855] [43974]
[65157] [65170]
Halothane: (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]
Histrelin: (Major) Avoid coadministration of azithromycin with histrelin due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [30369] [43974] [65157] [65170]
Hydroxychloroquine: (Major) Avoid coadministration of hydroxychloroquine and azithromycin due the risk of additive 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances (See Therapeutic Drug Monitoring for recommendations specific to COVID-19). Hydroxychloroquine 
prolongs the QT interval. QT prolongation and torsade de pointe (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. [28855] [41806] [43974] [65157] [65170]
Hydroxyzine: (Major) Avoid coadministration of azithromycin with hydroxyzine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Postmarketing data indicate that hydroxyzine causes QT prolongation and TdP. [28855]
[43974] [47129] [65157] [65170]
Ibutilide: (Major) Avoid coadministration of azithromycin with ibutilide due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Ibutilide administration can cause QT prolongation and TdP; proarrhythmic events should be anticipated. 
The potential for proarrhythmic events with ibutilide increases with the coadministration of other drugs that prolong 
the QT interval. [28855] [41830] [43974] [65157] [65170]
Iloperidone: (Major) Avoid coadministration of azithromycin with iloperidone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Iloperidone has been associated with QT prolongation. [28855] [36146] [43974] [65157]
[65170]
Imipramine: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Indacaterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]
Indacaterol; Glycopyrrolate: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Inotuzumab Ozogamicin: (Major) Avoid coadministration of inotuzumab ozogamicin with azithromycin due to the 
potential for additive QT interval prolongation and risk of torsade de pointes (TdP). If coadministration is unavoidable, 
obtain an ECG and serum electrolytes prior to the start of treatment, after treatment initiation, and periodically during 
treatment. Avoid any non-essential QT prolonging drugs and correct electrolyte imbalances. Inotuzumab has been 
associated with QT interval prolongation. QT prolongation and TdP have been spontaneously reported during 
azithromycin postmarketing surveillance. [28855] [43974] [62245] [65157] [65170]
Isoflurane: (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]
Itraconazole: (Major) Avoid coadministration of azithromycin with itraconazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Itraconazole has been associated with prolongation of the QT interval. [28855] [40233]
[43974] [57441] [65157] [65170]
Ivosidenib: (Major) Avoid coadministration of azithromycin with ivosidenib due to an increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. An interruption of therapy and dose reduction of ivosidenib may be necessary if QT prolongation occurs. 
Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. [28855] [43974] [63368] [65157] [65170]
Ketoconazole: (Major) Avoid coadministration of azithromycin with ketoconazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Ketoconazole has been associated with prolongation of the QT interval. [27982] [28855]
[43974] [65157] [65170]
Lapatinib: (Major) Avoid coadministration of azithromycin with lapatinib due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Lapatinib has been associated with concentration-dependent QT prolongation; ventricular arrhythmias 
and TdP have been reported in postmarketing experience with lapatinib. [28855] [33192] [43974] [65157] [65170]
Lefamulin: (Major) Avoid coadministration of azithromycin with lefamulin as concurrent use may increase the risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs. and correct electrolyte 
imbalances. Lefamulin has a concentration dependent QTc prolongation effect. The pharmacodynamic interaction 
potential to prolong the QT interval of the electrocardiogram between lefamulin and other drugs that effect cardiac 
conduction is unknown. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. [28855] [43974] [64576] [65157] [65170]
Lenvatinib: (Major) Avoid coadministration of azithromycin with lenvatinib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Prolongation of the QT interval has been reported with lenvatinib therapy. [28855] [43974]
[58782] [65157] [65170]
Leuprolide: (Major) Avoid coadministration of azithromycin with leuprolide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [43800] [43974]
[65157] [65170]
Leuprolide; Norethindrone: (Major) Avoid coadministration of azithromycin with leuprolide due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [43800] [43974]
[65157] [65170] (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Levalbuterol: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Levofloxacin: (Major) Avoid coadministration of azithromycin with levofloxacin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Levofloxacin has been associated with a risk of QT prolongation and TdP. Although 
extremely rare, TdP has been reported during postmarketing surveillance of levofloxacin. [28421] [28855] [43974] [65157]
[65170]
Levonorgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Lithium: (Major) Avoid coadministration of azithromycin with lithium due to the increased risk of QT prolongation. If 
use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Lithium has also been associated with QT prolongation. [28855] [43974] [59809] [59810] [59811] [65157]
[65170]
Lofexidine: (Major) Avoid coadministration of azithromycin with lofexidine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Lofexidine prolongs the QT interval. [28855] [43974] [63161] [65157] [65170]
Long-acting beta-agonists: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Loperamide: (Major) Avoid coadministration of azithromycin with loperamide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. At high doses, loperamide has been associated with serious cardiac toxicities, including 
syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. [28855] [30106] [43974] [60864] [65157]
[65170]
Loperamide; Simethicone: (Major) Avoid coadministration of azithromycin with loperamide due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. At high doses, loperamide has been associated with serious cardiac toxicities, including 
syncope, ventricular tachycardia, QT prolongation, TdP, and cardiac arrest. [28855] [30106] [43974] [60864] [65157]
[65170]
Lopinavir; Ritonavir: (Major) Avoid coadministration of azithromycin with lopinavir; ritonavir due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Lopinavir; ritonavir is associated with QT prolongation. [28341] [28855]
[43974] [65157] [65170]
Macimorelin: (Major) Avoid coadministration of azithromycin with macimorelin due to the increased risk of QT 
prolongation and torsade de pointes-type ventricular tachycardia. Sufficient washout time of drugs that are known to 
prolong the QT interval prior to administration of macimorelin is recommended. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have 
been spontaneously reported during azithromycin postmarketing surveillance. Treatment with macimorelin has been 
associated with an increase in the corrected QT (QTc) interval. [28855] [43974] [62723] [65150] [65157] [65170]
Magnesium Hydroxide: (Moderate) Antacids containing aluminum salts and/or magnesium salts can decrease the oral 
absorption of immediate-release azithromycin, resulting in lower peak plasma concentrations. If antacids must be 
taken, stagger the administration of the antacid and azithromycin. The extended-release suspension may be taken 
without regard to antacids containing magnesium hydroxide and/or aluminum hydroxide. [28855] [34473] [43975]
Maprotiline: (Major) Avoid coadministration of azithromycin with maprotiline due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Maprotiline has been reported to prolong the QT interval, particularly in overdose or with 
higher-dose prescription therapy (elevated serum concentrations). Cases of long QT syndrome and TdP tachycardia 
have been described with maprotiline use, but rarely occur when the drug is used alone in normal prescribed doses and 
in the absence of other known risk factors for QT prolongation. Limited data are available regarding the safety of 
maprotiline in combination with other QT-prolonging drugs. [28759] [28855] [43974] [65157] [65170]
Mefloquine: (Major) Avoid coadministration of azithromycin with mefloquine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. There is evidence that the use of halofantrine after mefloquine causes a significant 
lengthening of the QTc interval. Mefloquine alone has not been reported to cause QT prolongation. [28301] [28855]
[43974] [65157] [65170]
Meperidine; Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225]
[28855] [43974] [55578] [65157] [65170]
Mestranol; Norethindrone: (Moderate) It would be prudent to recommend alternative or additional contraception when 
oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may 
decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in 
enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Metaproterenol: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Methadone: (Major) Avoid coadministration of azithromycin with methadone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Methadone is considered to be associated with an increased risk for QT prolongation and 
TdP, especially at higher doses (more than 200 mg/day but averaging approximately 400 mg/day in adult patients). 
Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have 
been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. [28319] [28320]
[28321] [28322] [28855] [33136] [43974] [65157] [65170]
Metronidazole: (Major) Avoid coadministration of azithromycin with metronidazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Potential QT prolongation has been reported in limited case reports with metronidazole. 
[28855] [43974] [57377] [57378] [65157] [65170]
Midostaurin: (Major) Avoid coadministration of azithromycin with midostaurin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs. and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation was reported in patients who received midostaurin in clinical trials. 
[28855] [43974] [61906] [65157] [65170]
Mifepristone: (Major) Avoid coadministration of azithromycin with mifepristone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Mifepristone has been associated with dose-dependent prolongation of the QT interval. 
[28855] [43974] [48697] [65157] [65170]
Mirtazapine: (Major) Avoid coadministration of azithromycin with mirtazapine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Mirtazapine has been associated with dose-dependent prolongation of the QT interval. TdP 
has been reported postmarketing, primarily in overdose or in patients with other risk factors for QT prolongation. 
[28855] [40942] [43974] [65157] [65170]
Moxifloxacin: (Major) Avoid coadministration of azithromycin with moxifloxacin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Quinolones have been associated with a risk of QT prolongation. Although extremely rare, 
TdP has been reported during postmarketing surveillance of moxifloxacin. These reports generally involved patients 
with concurrent medical conditions or concomitant medications that may have been contributory. [28423] [28855]
[43974] [65157] [65170]
Nelfinavir: (Moderate) Coadministration of nelfinavir and azithromycin results in increased azithromycin 
concentrations. Dosage adjustments are not necessary, although patients should be monitored for azithromycin related 
adverse effects such as increased hepatic enzymes and hearing impairment. [28839] [34329]
Nilotinib: (Major) Avoid coadministration of azithromycin with nilotinib due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Sudden death and QT prolongation have been reported in patients who received nilotinib therapy. [28855]
[43974] [58766] [65157] [65170]
Norethindrone: (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Norgestrel: (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Nortriptyline: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Octreotide: (Major) Avoid coadministration of azithromycin with octreotide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during 
octreotide therapy. Since bradycardia is a risk factor for development of TdP, the potential occurrence of bradycardia 
during octreotide administration could theoretically increase the risk of TdP in patients receiving drugs that prolong the 
QT interval. [28432] [28855] [29113] [30624] [43974] [65157] [65170]
Ofloxacin: (Major) Avoid coadministration of azithromycin with ofloxacin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Quinolones have been associated with a risk of QT prolongation and TdP. Although 
extremely rare, TdP has been reported during postmarketing surveillance of ofloxacin. These reports generally involved 
patients with concurrent medical conditions or concomitant medications that may have been contributory. [28855]
[30738] [43974] [65157] [65170]
Olanzapine: (Major) Avoid coadministration of azithromycin with olanzapine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Limited data, including some case reports, suggest that olanzapine may be associated with 
a significant prolongation of the QTc interval. [28785] [28855] [32732] [32734] [32745] [32746] [43974] [65157] [65170]
Olodaterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]
Ondansetron: (Major) Avoid coadministration of azithromycin with ondansetron due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Ondansetron has been associated with a dose-related increase in the QT interval and 
postmarketing reports of TdP. [28855] [31266] [32722] [43974] [65157] [65170]
Oral Contraceptives: (Moderate) It would be prudent to recommend alternative or additional contraception when oral 
contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that antibiotics may decrease 
the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction in enterohepatic 
circulation via changes in GI flora. One retrospective study reviewed the literature to determine the effects of oral 
antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined clinical studies in 
which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the antibiotics 
ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, temafloxacin, and 
tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were the only agents 
associated with OC failure and pregnancy. Based on the study results, these authors recommended that back-up 
contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review concurred with 
these data, but noted that individual patients have been identified who experienced significant decreases in plasma 
concentrations of combined OC components and who appeared to ovulate; the agents most often associated with these 
changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that because females most at 
risk for OC failure or noncompliance may not be easily identified and the true incidence of such events may be under-
reported, and given the serious consequence of unwanted pregnancy, that recommending an additional method of 
contraception during short-term antibiotic use may be justified. During long-term antibiotic administration, the risk for 
drug interaction with OCs is less clear, but alternative or additional contraception may be advisable in selected 
circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive deliveries (e.g., 
patches, rings) are not available. [28482] [28509]
Osilodrostat: (Major) Avoid coadministration of azithromycin with osilodrostat due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Osilodrostat is associated with dose-dependent QT prolongation. [28855] [43974] [65098]
[65157] [65170]
Osimertinib: (Major) Avoid coadministration of azithromycin with osimertinib if possible due to the risk of QT 
prolongation and torsade de pointes (TdP). If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and 
correct electrolyte imbalances. An interruption of osimertinib therapy with dose reduction or discontinuation may be 
necessary if QT prolongation occurs. QT prolongation and TdP have been spontaneously reported during azithromycin 
postmarketing surveillance. Concentration-dependent QTc prolongation occurred during clinical trials of osimertinib. 
[28855] [43974] [60297] [65157] [65170]
Oxaliplatin: (Major) Avoid coadministration of azithromycin with oxaliplatin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation and ventricular arrhythmias including fatal TdP have been reported with 
oxaliplatin use in postmarketing experience. [28855] [41958] [43974] [65157] [65170]
Paliperidone: (Major) Avoid coadministration of azithromycin with paliperidone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Paliperidone has been associated with QT prolongation; torsade de pointes and ventricular 
fibrillation have been reported in the setting of overdose. [28855] [40936] [43974] [65157] [65170]
Panobinostat: (Major) Avoid coadministration of azithromycin with panobinostat due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation has been reported with panobinostat. [28855] [43974] [58821] [65157]
[65170]
Pasireotide: (Major) Avoid coadministration of azithromycin with pasireotide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. QT prolongation has also occurred with pasireotide at therapeutic and supra-therapeutic 
doses. [28855] [43974] [52611] [65157] [65170]
Pazopanib: (Major) Avoid coadministration of azithromycin with pazopanib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Pazopanib has been reported to prolong the QT interval. [28855] [37098] [43974] [65157]
[65170]
Pentamidine: (Major) Avoid coadministration of azithromycin with pentamidine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Systemic pentamidine has been associated with QT prolongation. [23620] [23778] [28419]
[28855] [28879] [43974] [65157] [65170]
Perphenazine: (Major) Avoid coadministration of azithromycin with perphenazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Perphenazine is associated with a possible risk for QT prolongation. Theoretically, 
perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT 
prolongation. [28415] [28855] [43974] [65157] [65170]
Perphenazine; Amitriptyline: (Major) Avoid coadministration of azithromycin with perphenazine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Perphenazine is associated with a possible risk for QT prolongation. 
Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a 
risk of QT prolongation. [28415] [28855] [43974] [65157] [65170] (Major) Avoid coadministration of azithromycin with 
tricyclic antidepressants (TCAs) due to the increased risk of QT prolongation. If use together is necessary, obtain an 
ECG at baseline to assess initial QT interval and determine frequency of subsequent ECG monitoring, avoid any non-
essential QT prolonging drugs, and correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have 
been spontaneously reported during azithromycin postmarketing surveillance. TCAs share pharmacologic properties 
similar to the Class IA antiarrhythmic agents and may prolong the QT interval, particularly in overdose or with higher-
dose prescription therapy (elevated serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Phenylephrine; Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the increased 
risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and 
determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225]
[28855] [43974] [55578] [65157] [65170]
Phenytoin: (Minor) Until more data are available, the manufacturer of azithromycin recommends caution and careful 
monitoring of patients who receive azithromycin with phenytoin. Azithromycin was not implicated in clinical trials 
with drug interactions with phenytoin. However, specific drug interaction studies have not been performed with the 
combination of azithromycin and phenytoin. [28855]
Pimavanserin: (Major) Avoid coadministration of azithromycin with pimavanserin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Pimavanserin prolongs the QT interval. [28855] [43974] [60748] [65157] [65170]
Pimozide: (Severe) Pimozide is associated with a well-established risk of QT prolongation and torsade de pointes 
(TdP). Because of the potential for TdP, use of macrolide antibiotics with pimozide is contraindicated. [28225] [28855]
[43258] [43463] [59321]
Pirbuterol: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Pitolisant: (Major) Avoid coadministration of azithromycin with pitolisant due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Pitolisant prolongs the QT interval. [28855] [43974] [64562] [65157] [65170]
Posaconazole: (Major) Avoid coadministration of azithromycin with posaconazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Posaconazole has been associated with prolongation of the QT interval as well as rare 
cases of TdP. [28855] [32723] [43974] [65157] [65170]
Pravastatin: (Moderate) Azithromycin has the potential to increase pravastatin exposure when used concomitantly. 
Coadminister pravastatin and azithromycin cautiously due to a potential increased risk of myopathies. [45507]
Primaquine: (Major) Avoid coadministration of azithromycin with primaquine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Primaquine has the potential for QT interval prolongation. [28855] [41984] [43974] [65157]
[65170]
Procainamide: (Major) Avoid coadministration of azithromycin with procainamide due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Procainamide is associated with a well-established risk of QT prolongation and TdP. 
[28250] [28855] [43974] [65157] [65170]
Prochlorperazine: (Major) Avoid coadministration of azithromycin with prochlorperazine due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, 
prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT 
prolongation. [28415] [28855] [43974] [65157] [65170]
Promethazine: (Major) Avoid coadministration of azithromycin with promethazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Promethazine is associated with possible risk for QT prolongation. [28225] [28855] [43974]
[55578] [65157] [65170]
Propafenone: (Major) Avoid coadministration of azithromycin with propafenone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Propafenone is a Class IC antiarrhythmic which increases the QT interval, but largely due 
to prolongation of the QRS interval. [28287] [28855] [43974] [65157] [65170]
Protriptyline: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Quetiapine: (Major) Avoid coadministration of azithromycin with quetiapine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Limited data, including some case reports, suggest that quetiapine may be associated with 
a significant prolongation of the QTc interval in rare instances. [28855] [29118] [33068] [33072] [33074] [43974] [65157]
[65170]
Quinidine: (Major) Avoid coadministration of azithromycin with quinidine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Quinidine administration is associated with QT prolongation and TdP. [28855] [42280]
[43974] [47357] [65157] [65170]
Quinine: (Major) Avoid coadministration of azithromycin with quinine due to the increased risk of QT prolongation. If 
use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Quinine has been associated with QT prolongation and rare cases of TdP. [28855] [31403] [43974] [65157]
[65170]
Ranolazine: (Major) Avoid coadministration of azithromycin with ranolazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Ranolazine is associated with dose- and plasma concentration-related increases in the QTc 
interval. Although there are no studies examining the effects of ranolazine in patients receiving other QT prolonging 
drugs, coadministration of such drugs may result in additive QT prolongation. [28855] [31938] [43974] [65157] [65170]
Ribociclib: (Major) Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Ribociclib has been shown to prolong the QT interval in a concentration-dependent 
manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose 
interruption. [28855] [43974] [61816] [65157] [65170]
Ribociclib; Letrozole: (Major) Avoid coadministration of azithromycin with ribociclib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Ribociclib has been shown to prolong the QT interval in a concentration-dependent 
manner. The ribociclib ECG changes occurred within the first four weeks of treatment and were reversible with dose 
interruption. [28855] [43974] [61816] [65157] [65170]
Rilpivirine: (Major) Avoid coadministration of azithromycin with rilpivirine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Supratherapeutic doses of rilpivirine (75 to 300 mg/day) have caused QT prolongation. 
[28855] [43974] [44376] [65157] [65170]
Risperidone: (Major) Avoid coadministration of azithromycin with risperidone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Risperidone has been associated with a possible risk for QT prolongation and/or TdP, 
primarily in the overdose setting. [28225] [28414] [28416] [28855] [43974] [65157] [65170]
Romidepsin: (Major) Avoid coadministration of azithromycin with romidepsin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Romidepsin has been reported to prolong the QT interval. [28855] [37292] [43974] [65157]
[65170]
Salmeterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157] [65170]
Saquinavir: (Major) Avoid coadministration of azithromycin with saquinavir boosted with ritonavir due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Saquinavir boosted with ritonavir increases the QT interval in a dose-
dependent fashion, which may increase the risk for serious arrhythmias such as TdP. [28855] [28995] [43974] [65157]
[65170]
Segesterone Acetate; Ethinyl Estradiol: (Moderate) It would be prudent to recommend alternative or additional 
contraception when oral contraceptives (OCs) are used in conjunction with antibiotics. It was previously thought that 
antibiotics may decrease the effectiveness of OCs containing estrogens due to stimulation of metabolism or a reduction 
in enterohepatic circulation via changes in GI flora. One retrospective study reviewed the literature to determine the 
effects of oral antibiotics on the pharmacokinetics of contraceptive estrogens and progestins, and also examined 
clinical studies in which the incidence of pregnancy with OCs and antibiotics was reported. It was concluded that the 
antibiotics ampicillin, ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin, roxithromycin, 
temafloxacin, and tetracycline did not alter plasma concentrations of OCs. Antituberculous drugs (e.g., rifampin) were 
the only agents associated with OC failure and pregnancy. Based on the study results, these authors recommended that 
back-up contraception may not be necessary if OCs are used reliably during oral antibiotic use. Another review 
concurred with these data, but noted that individual patients have been identified who experienced significant 
decreases in plasma concentrations of combined OC components and who appeared to ovulate; the agents most often 
associated with these changes were rifampin, tetracyclines, and penicillin derivatives. These authors concluded that 
because females most at risk for OC failure or noncompliance may not be easily identified and the true incidence of 
such events may be under-reported, and given the serious consequence of unwanted pregnancy, that recommending an 
additional method of contraception during short-term antibiotic use may be justified. During long-term antibiotic 
administration, the risk for drug interaction with OCs is less clear, but alternative or additional contraception may be 
advisable in selected circumstances. Data regarding progestin-only contraceptives or for newer combined contraceptive 
deliveries (e.g., patches, rings) are not available. [28482] [28509]
Sertraline: (Major) Avoid coadministration of azithromycin with sertraline due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Sertraline's FDA-approved labeling recommends avoiding concomitant use with drugs 
known to prolong the QTc interval; however, the risk of sertraline-induced QT prolongation is generally considered to 
be low in clinical practice. Its effect on QTc interval is minimal (typically less than 5 msec), and the drug has been used 
safely in patients with cardiac disease (e.g., recent myocardial infarction, unstable angina, chronic heart failure). 
[28343] [28855] [43974] [64391] [64392] [64394] [64395] [64396] [65157] [65170]
Sevoflurane: (Major) Avoid coadministration of azithromycin with halogenated anesthetics due to the increased risk of 
QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Halogenated anesthetics can prolong the QT interval. [28458] [28855] [43974] [65157] [65170]
Short-acting beta-agonists: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Siponimod: (Major) Avoid coadministration of azithromycin with siponimod due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Siponimod therapy prolonged the QT interval at recommended doses in a clinical study. 
[28855] [43974] [64031] [65157] [65170]
Sodium picosulfate; Magnesium oxide; Anhydrous citric acid: (Major) Prior or concomitant use of antibiotics with 
sodium picosulfate; magnesium oxide; anhydrous citric acid may reduce efficacy of the bowel preparation as 
conversion of sodium picosulfate to its active metabolite bis-(p-hydroxy-phenyl)-pyridyl-2-methane (BHPM) is 
mediated by colonic bacteria. If possible, avoid coadministration. Certain antibiotics (i.e., tetracyclines and quinolones) 
may chelate with the magnesium in sodium picosulfate; magnesium oxide; anhydrous citric acid solution. Therefore, 
these antibiotics should be taken at least 2 hours before and not less than 6 hours after the administration of sodium 
picosulfate; magnesium oxide; anhydrous citric acid solution. [51258]
Solifenacin: (Major) Avoid coadministration of azithromycin with solifenacin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Solifenacin has been associated with dose-dependent prolongation of the QT interval. TdP 
has been reported with postmarketing use, although causality was not determined. [28855] [30515] [43974] [65157]
[65170]
Sorafenib: (Major) Avoid coadministration of azithromycin with sorafenib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. An interruption or discontinuation of sorafenib therapy may be necessary if QT prolongation occurs. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Sorafenib has been associated with QT prolongation. [28855] [31832] [43974] [65157] [65170]
Sotalol: (Major) Avoid coadministration of azithromycin with sotalol due to the increased risk of QT prolongation. If 
use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Sotalol administration is associated with QT prolongation and TdP. Proarrhythmic events should be 
anticipated after initiation of therapy and after each upward dosage adjustment. [28234] [28855] [43974] [65157] [65170]
Sunitinib: (Major) Avoid coadministration of azithromycin with sunitinib due to the increased risk of QT prolongation. 
If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine frequency of 
subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte imbalances. QT 
prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin postmarketing 
surveillance. Sunitinib can cause dose-dependent QT prolongation, which may increase the risk for ventricular 
arrhythmias, including TdP. [28855] [31970] [43974] [65157] [65170]
Tacrolimus: (Major) Avoid coadministration of azithromycin with tacrolimus due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Tacrolimus may prolong the QT interval and cause TdP. [27353] [27354] [28225] [28855]
[43974] [65157] [65170]
Talazoparib: (Moderate) Monitor for an increase in talazoparib-related adverse reactions if coadministration with 
azithromycin is necessary. In clinical trials, coadministration with azithromycin increased talazoparib exposure by 
approximately 8%. [63651]
Tamoxifen: (Major) Avoid coadministration of azithromycin with tamoxifen due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used 
in high doses. Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses. 
[28855] [43974] [61870] [61871] [61872] [63589] [65157] [65170]
Telavancin: (Major) Avoid coadministration of azithromycin with telavancin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Telavancin has been associated with QT prolongation. [28855] [36615] [43974] [65157]
[65170]
Telithromycin: (Major) Avoid coadministration of azithromycin with telithromycin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Telithromycin is also associated with QT prolongation and TdP. [28156] [28855] [43974]
[65157] [65170]
Terbutaline: (Major) Avoid coadministration of azithromycin with short-acting beta-agonists due to the increased risk 
of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects including QT interval 
prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to 
prolong the QT interval. This risk may be more clinically significant with long-acting beta-agonists as compared to 
short-acting beta-agonists. [28318] [28855] [33925] [43974] [65157] [65170]
Tetrabenazine: (Major) Avoid coadministration of azithromycin with tetrabenazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Tetrabenazine causes a small increase in the corrected QT interval (QTc). [28855] [34389]
[43974] [65157] [65170]
Thioridazine: (Severe) Coadministration of thioridazine and azithromycin is contraindicated due to an increased risk of 
QT prolongation. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Thioridazine is associated with a well-established risk of QT prolongation and TdP. [28225]
[28293] [28855] [43974]
Tiotropium; Olodaterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Tolterodine: (Major) Avoid coadministration of azithromycin with tolterodine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Tolterodine has been associated with dose-dependent prolongation of the QT interval, 
especially in poor CYP2D6 metabolizers. [28855] [31112] [43974] [65157] [65170]
Toremifene: (Major) Avoid coadministration of azithromycin with toremifene if possible due to the risk of additive QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Toremifene has been shown to prolong the QTc interval in a dose- and concentration-
related manner. [28822] [28855] [43974] [65157] [65170]
Trazodone: (Major) Avoid coadministration of azithromycin with trazodone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Trazodone can prolong the QT/QTc interval at therapeutic doses. In addition, there are 
postmarketing reports of TdP. [28855] [43974] [65157] [65170]
Tricyclic antidepressants: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to 
the increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and 
correct electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Trifluoperazine: (Major) Avoid coadministration of azithromycin with trifluoperazine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Trifluoperazine is associated with a possible risk for QT prolongation. Theoretically, 
trifluoperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT 
prolongation. [28415] [28855] [43974] [65157] [65170]
Trimipramine: (Major) Avoid coadministration of azithromycin with tricyclic antidepressants (TCAs) due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. TCAs share pharmacologic properties similar to the Class IA antiarrhythmic 
agents and may prolong the QT interval, particularly in overdose or with higher-dose prescription therapy (elevated 
serum concentrations). [28225] [28415] [28416] [28855] [43974] [65157] [65170]
Triptorelin: (Major) Avoid coadministration of azithromycin with triptorelin due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Androgen deprivation therapy may prolong the QT/QTc interval. [28855] [43974] [45411]
[65157] [65170]
Umeclidinium; Vilanterol: (Major) Avoid coadministration of azithromycin with long-acting beta-agonists due to the 
increased risk of QT prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval 
and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct 
electrolyte imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during 
azithromycin postmarketing surveillance. Beta-agonists may be associated with adverse cardiovascular effects 
including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with 
other drugs known to prolong the QT interval. This risk may be more clinically significant with long-acting beta-
agonists as compared to short-acting beta-agonists. [28467] [28855] [32901] [41231] [43974] [44979] [54633] [57710] [65157]
[65170]
Vandetanib: (Major) Avoid coadministration of azithromycin with vandetanib due to an increased risk of QT 
prolongation and torsade de pointes (TdP). If use together is necessary, obtain an ECG at baseline to assess initial QT 
interval and determine frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and 
correct electrolyte imbalances. An interruption of vandetanib therapy or dose reduction may be necessary for QT 
prolongation. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Vandetanib can prolong the QT interval in a concentration-dependent manner; TdP and 
sudden death have been reported in patients receiving vandetanib. [28855] [43901] [43974] [65157] [65170]
Vardenafil: (Major) Avoid coadministration of azithromycin with vardenafil due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Both therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc 
interval. [28216] [28855] [41124] [43974] [65157] [65170]
Vemurafenib: (Major) Avoid coadministration of azithromycin with vemurafenib due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Vemurafenib has been associated with QT prolongation. [28855] [43974] [45335] [65157]
[65170]
Venlafaxine: (Major) Avoid coadministration of azithromycin with venlafaxine due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Venlafaxine administration is associated with a possible risk of QT prolongation; TdP has 
reported with postmarketing use. [28855] [33715] [43974] [65157] [65170]
Voriconazole: (Major) Avoid coadministration of azithromycin with voriconazole due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Voriconazole has been associated with prolongation of the QT interval and rare cases of 
arrhythmias, including TdP. [28158] [28855] [43974] [65157] [65170]
Vorinostat: (Major) Avoid coadministration of azithromycin with vorinostat due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Vorinostat is associated with a risk of QT prolongation. [28855] [32789] [43974] [65157]
[65170]
Warfarin: (Moderate) Carefully monitor the PT/INR in patients who receive warfarin and azithromycin concomitantly. 
Postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral 
warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and 
warfarin. [23809] [28855]
Ziprasidone: (Major) Avoid coadministration of azithromycin with ziprasidone due to the increased risk of QT 
prolongation. If use together is necessary, obtain an ECG at baseline to assess initial QT interval and determine 
frequency of subsequent ECG monitoring, avoid any non-essential QT prolonging drugs, and correct electrolyte 
imbalances. QT prolongation and torsade de pointes (TdP) have been spontaneously reported during azithromycin 
postmarketing surveillance. Clinical trial data indicate that ziprasidone causes QT prolongation; there are 
postmarketing reports of TdP in patients with multiple confounding factors. [28233] [28855] [43974] [65157] [65170]
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Admixture Syringe Y-Site Administration For Dilution
Acyclovir sodium ND ND ND 
Alatrofloxacin mesylate ND ND ND 
Alemtuzumab ND ND ND 
Alfentanil hydrochloride ND ND ND 
Amikacin sulfate ND ND ND 
Aminocaproic acid ND ND ND 
Aminophylline ND ND ND 
Amiodarone hydrochloride ND ND ND 
Amphotericin B conventional colloidal ND ND ND 
Amphotericin B lipid complex (Abelcet) ND ND ND 
Amphotericin B liposome (AmBisome) ND ND ND 
Ampicillin sodium ND ND ND 
Ampicillin sodium-sulbactam sodium ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Anidulafungin ND ND ND 
Argatroban ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Arsenic trioxide ND ND ND 
Asparaginase ND ND ND 
Atenolol ND ND ND 
Atracurium besylate ND ND ND 
Aztreonam ND ND ND 
Bivalirudin ND ND ND 
Bleomycin sulfate ND ND ND 
Bumetanide ND ND ND 
Buprenorphine hydrochloride ND ND ND 
Butorphanol tartrate ND ND ND 
Calcium chloride ND ND ND 
Calcium gluconate ND ND ND 
Cangrelor ND ND ND 
Capreomycin sulfate ND ND ND 
Carboplatin ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Carmustine ND ND ND 
Caspofungin acetate ND ND ND 
Cefazolin sodium ND ND ND 
Cefepime hydrochloride ND ND ND 
Cefoperazone ND ND ND 
Cefotaxime ND ND ND 
Cefotetan disodium ND ND ND 
Cefoxitin ND ND ND 
Ceftaroline fosamil ND ND ND 
Ceftazidime ND ND ND 
Ceftazidime (L-arginine) ND ND ND 
Ceftizoxime ND ND ND 
Ceftobiprole medocaril ND ND ND 
Ceftolozane; Tazobactam ND ND ND 
Ceftriaxone sodium ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Cefuroxime ND ND ND 
Chlorpromazine hydrochloride ND ND ND 
Cimetidine hydrochloride ND ND ND 
Ciprofloxacin ND ND 
Cisatracurium besylate ND ND ND 
Cisplatin ND ND ND 
Clindamycin phosphate ND ND ND 
Cloxacillin sodium ND ND ND 
Cyclophosphamide ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Cyclosporine ND ND ND 
Cytarabine ND ND ND 
D5W-Dextrose 5% ND ND ND 
Dacarbazine ND ND ND 
Daptomycin ND ND 
Daunorubicin citrate liposome ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Dexamethasone sodium phosphate ND ND ND 
Dexmedetomidine hydrochloride ND ND ND 
Dexrazoxane ND ND ND 
Dextrose 5% in lactated Ringer's ND ND ND 
Dextrose 5% in sodium chloride 0.3% ND ND ND 
Dextrose 5% in sodium chloride 0.45% ND ND ND 
Diazepam ND ND ND 
Digoxin ND ND ND 
Diltiazem hydrochloride ND ND ND 
Diphenhydramine hydrochloride ND ND ND 
Dobutamine hydrochloride ND ND ND 
Docetaxel ND ND ND 
Dolasetron mesylate ND ND ND 
Dopamine hydrochloride ND ND ND 
Doripenem ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Doxacurium chloride ND ND ND 
Doxorubicin hydrochloride ND ND ND 
Doxorubicin hydrochloride liposomal ND ND ND 
Doxycycline hyclate ND ND ND 
Droperidol ND ND ND 
Enalaprilat ND ND ND 
Ephedrine hydrochloride ND ND ND 
Epinephrine hydrochloride ND ND ND 
Epirubicin hydrochloride ND ND ND 
Eptifibatide ND ND ND 
Ertapenem sodium ND ND ND 
Esmolol hydrochloride ND ND ND 
Etoposide ND ND ND 
Etoposide phosphate ND ND ND 
Famotidine ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Fenoldopam mesylate ND ND ND 
Fentanyl citrate ND ND ND 
Fluconazole ND ND ND 
Fluorouracil ND ND ND 
Foscarnet sodium ND ND ND 
Fosphenytoin sodium ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Furosemide ND ND ND 
Gallium nitrate ND ND ND 
Ganciclovir sodium ND ND ND 
Garenoxacin Mesylate ND ND ND 
Gatifloxacin ND ND ND 
Gemcitabine hydrochloride ND ND ND 
Gemtuzumab ozogamicin ND ND ND 
Gentamicin sulfate ND ND ND 
Granisetron hydrochloride ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Haloperidol lactate ND ND ND 
Heparin sodium ND ND ND 
Hetastarch 6% (Hextend) ND ND ND 
Hydrocortisone sodium phosphate ND ND ND 
Hydrocortisone sodium succinate ND ND ND 
Hydromorphone hydrochloride ND ND ND 
Hydroxyzine hydrochloride ND ND ND 
Idarubicin hydrochloride ND ND ND 
Ifosfamide ND ND ND 
Imipenem-cilastatin sodium ND ND ND 
Inamrinone lactate ND ND ND 
Irinotecan hydrochloride ND ND ND 
Isavuconazonium Sulfate ND ND ND 
Isoproterenol hydrochloride ND ND ND 
Ketorolac tromethamine ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Labetalol hydrochloride ND ND ND 
Lactated Ringer's Injection ND ND ND 
Lepirudin ND ND ND 
Leucovorin calcium ND ND ND 
Levofloxacin ND ND ND 
Levorphanol tartrate ND ND ND 
Lidocaine hydrochloride ND ND ND 
Linezolid ND ND ND 
Lorazepam ND ND ND 
Magnesium sulfate ND ND ND 
Mannitol ND ND ND 
Mechlorethamine hydrochloride ND ND ND 
Meperidine hydrochloride ND ND ND 
Meropenem ND ND ND 
Mesna ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Methadone hydrochloride ND ND ND 
Methohexital sodium ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Methotrexate sodium ND ND ND 
Methylprednisolone sodium succinate ND ND ND 
Metoclopramide hydrochloride ND ND ND 
Metronidazole ND ND ND 
Midazolam hydrochloride ND ND ND 
Milrinone lactate ND ND ND 
Minocycline hydrochloride ND ND ND 
Mitoxantrone hydrochloride ND ND ND 
Mivacurium chloride ND ND ND 
Morphine sulfate ND ND ND 
Mycophenolate mofetil hydrochloride ND ND ND 
Nalbuphine hydrochloride ND ND ND 
Naloxone hydrochloride ND ND 
Admixture Syringe Y-Site Administration For Dilution
Nesiritide ND ND ND 
Nicardipine hydrochloride ND ND ND 
Nitroglycerin ND ND ND 
Nitroprusside sodium ND ND ND 
Normal saline- Sodium chloride 0.9% ND ND ND 
Normosol M in dextrose 5% ND ND ND 
Normosol R in dextrose 5% ND ND ND 
Octreotide acetate ND ND ND 
Ofloxacin ND ND ND 
Ondansetron hydrochloride ND ND ND 
Ornidazole ND ND ND 
Oxaliplatin ND ND ND 
Oxytocin ND ND ND 
Paclitaxel (solvent/surfactant) ND ND ND 
Palonosetron hydrochloride ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Pamidronate disodium ND ND ND 
Pancuronium bromide ND ND ND 
Pantoprazole sodium ND ND ND 
Pemetrexed disodium ND ND ND 
Pentamidine isethionate ND ND ND 
Pentobarbital sodium ND ND ND 
Phenobarbital sodium ND ND ND 
Phenylephrine hydrochloride ND ND ND 
Phenytoin sodium ND ND ND 
Piperacillin sodium ND ND ND 
Piperacillin sodium-tazobactam sodium ND ND ND 
Plazomicin ND ND ND 
Potassium acetate ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Potassium chloride ND ND 
Potassium phosphates ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Procainamide hydrochloride ND ND ND 
Prochlorperazine edisylate ND ND ND 
Promethazine hydrochloride ND ND ND 
Propranolol hydrochloride ND ND ND 
Quinupristin-Dalfopristin ND ND ND 
Ranitidine hydrochloride ND ND ND 
Remifentanil hydrochloride ND ND ND 
Rocuronium bromide ND ND ND 
Salbutamol ND ND ND 
Sodium acetate ND ND ND 
Sodium bicarbonate ND ND ND 
Sodium chloride 0.45% ND ND ND 
Sodium phosphates ND ND ND 
Succinylcholine chloride ND ND ND 
Sufentanil citrate ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Sulfamethoxazole-trimethoprim ND ND ND 
Tacrolimus ND ND ND 
Tedizolid phosphate ND ND ND 
Telavancin hydrochloride ND ND ND 
Teniposide ND ND ND 
Thiopental sodium ND ND ND 
Thiotepa ND ND ND 
Ticarcillin disodium ND ND ND 
Ticarcillin disodium-clavulanate potassium ND ND ND 
Tigecycline ND ND ND 
Tirofiban hydrochloride ND ND ND 
Tobramycin sulfate ND ND ND 
TPN (2-in-1) Total Parenteral Nutrition Admixture ND ND ND 
Trimethobenzamide hydrochloride ND ND ND 
Vancomycin hydrochloride ND ND ND 
Admixture Syringe Y-Site Administration For Dilution
Vasopressin ND ND ND 
Vecuronium bromide ND ND ND 
Verapamil hydrochloride ND ND ND 
VinCRIStine sulfate ND ND ND 
Voriconazole ND ND ND 
Zidovudine ND ND ND 
Zoledronic acid ND ND ND 
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US Drug Names
• Azasite
• Zithromax
• Zithromax Tri-Pak
• Zithromax Z-Pak
• Zmax
Global Drug names
Argentina
• Arzomicin - (Takeda)
• Azibiotic - (Baliarda)
• Azitral - (Sanitas)
• Azitrogal - (Sant Gall)
• Azitrolabsa - (Labsa)
• Azitrolan - (Lanpharm)
• Azitrona - (Klonal)
• Azitrox - (Lepetit)
• Cetaxim - (TRB)
• Clearsing - (Duncan)
• Cronopen - (Elea)
• Doyle - (Raffo)
• Fabodrox - (Fabop)
• Fabramicina - (Fabra)
• Finatres - (Finadiet)
• Macromax - (Investi)
• Misultina - (Bernabo)
• Naxocina - (AstraZeneca)
• Neblic - (Lazar)
• Nifostin - (Penn)
• Novozitron - (Laboratorio Internacional)
• Orobiotic - (Fortbenton)
• Sitrox - (Biotenk)
• Sumir - (Craveri)
• Talcilina - (Ronnet)
• Tanezox - (Microsules)
• Triamid - (Beta)
• Tritab - (Sidus)
• Tromiatlas - (Atlas)
• Vectocilina - (Panalab)
• Visag - (Poen)
• Zitromax - (Pfizer)
Australia
• Azith - (Alphapharm)
• Zedd - (Medis)
• Zithromax - (Pfizer)
• Zitrocin - (Pfizer)
Austria
• Azyter - (Thea)
• Zithromax - (Pfizer)
Belgium
• Zitromax - (Pfizer)
Brazil
• Astro - (Eurofarma)
• Atromicin - (Teuto)
• Azalide - (Bunker)
• Azatill - (Prodotti)
• Azi - (Sigma)
• Azidromic - (Royton)
• Azimax - (EMS)
• Azimed - (Cimed)
• Azimix - (Ativus)
• Azinostil - (EMS)
• Azitrax - (Farmoquimica)
• Azitrin - (Delta)
• Azitrocin - (Cibran)
• Azitrogran - (Legrand)
• Azitrolab - (Multilab)
• Azitromed - (Medquimica)
• Azitromicil - (Greenpharma)
• Azitromin - (Farmasa)
• Azitron - (Cifarma)
• Azitronax - (Pharlab)
• Azitrophar - (Pharlab)
• Azitrosol - (Luper)
• Azitroxil - (De Mayo)
• Biozitrom - (Biofarma)
• Clindal - (Merck)
• Clindaz - (Merck)
• Ems-Max - (EMS)
• Mac Azi - (Sigma)
• Mazitron - (Uniao Quimica)
• Novatrex - (Ache)
• Selimax - (Libbs)
• Selimax Pulso - (Libbs)
• Siftromin - (Sinterapico)
• Triazi - (Itaca)
• Tromix - (Ariston)
• Tromizir - (Belfar)
• Trozyman - (IQB)
• Zidimax - (Laboris)
• Zimicina - (Sandoz)
• Zitril - (Cazi)
• Zitromax - (Pfizer)
• Zitromil - (GSK)
• Zitroneo - (Neo Quimica)
• Zolprox - (Globo)
Canada
• Zithromax - (Pfizer)
• Zmax - (Pfizer)
• Z-Pak - (Pfizer)
Chile
• Abacten - (Andromaco)
• Asipral - (Labomed)
• Atizor - (Medipharm)
• Azibay - (Bayer)
• Azimit - (Interpharma)
• Azitrom - (Laboratorios Chile)
• Azydrop - (Andromaco)
• Ricilina - (Recalcine)
• Trex - (Saval)
• Zetamax - (Eurofarma)
• Zithromax - (Pfizer)
China
• A Sai Qi - (Yiqiao)
• Ai Mi Qi - (Mei Luo)
• An Mei Qin - (ZhenYuan)
• Ao Li Ping - (Aoya)
• Ba Qi - (Da Heng)
• Bai Ke De Rui - (Bai Ke)
• Bin Qi - (Qi Li)
• BinQi - (Binhu Shuanghe)
• Bo Kang - (Star)
• Chen Yu - (Lukang Chenxin)
• Feng Da Qi - (Asia Pioneer)
• Fu Qi-Hua Yuan - (Jinhui)
• Fu Rui Xin - (Lai En)
• Fuqixing - (Changzheng-Xinkai)
• Fuxin - (Haixin)
• Jin Nuo - (Fenghuang)
• Jin Pai Qi - (Lijun)
• Jinbo - (TianJin)
• Jun Jie - (Lunan)
• Jun Wei Qing - (Tianlong)
• Kai Qi - (Qianjiang)
• Kang Li Jian - (San Lian)
• Kang Qi - (Shunfeng)
• Ke Lin Da - (Liaoyuan Yadong)
• Ke Yan Li - (Liuan Huayuan)
• Kuai Di - (Hayao)
• Kuai Yu - (LuoXin)
• Li Ke Si - (Lai Mei)
• Li Li Kai - (Haishen Liansheng)
• Li Li Xing - (Haishen Liansheng)
• Li Qi - (Yangtze River)
• Lin Bi - (Double-Crane)
• Lipuqi - (Neptunus)
• Lipuxin - (Neptunus)
• Lizhu Qile - (Livzon)
• Lu Jia Kang - (Kanglong)
• Luo Bei Er - (Yong He)
• Luo Qi - (Aida)
• Luoxin Shoukang - (LuoXin)
• Ming Qi Xin - (Mingxin)
• Na Qi - (Pu Luo Kang Yu)
• Pai Fen - (Wanjie High Tech)
• Pai Fu - (Double-Crane)
• Paiqi - (Lijun)
• Pu He - (Chang Fu Jie Jing)
• Pu Le Qi - (Shyndec)
• Pu Yang - (Xin Ma)
• Qi Gu Mei - (Huang Long)
• Qi Hong - (Hayao)
• Qi Mai Xing - (Yatai)
• Qi Nuo - (Double-Crane)
• Qi Tai - (Jiu Tai)
• Qi Xian - (Shenyang First)
• QiLi - (Zhong Bao)
• Qiyue - (Jiqi Huakang)
• Ru Shuang Qi - (Kangliyuan)
• Rui Qi - (GuoRui)
• Rui Qi Lin - (Qian Long)
• Sai Jin Sha - (Tongde)
• Sai Le Xin - (United Lab)
• Sai Qi - (Dade)
• Sheng Nuo Ling - (Sanhome)
• Shepherd - (Ke Lun)
• Shu Luo Kang - (JiChuan)
• Su Shuang - (GuoGuang)
• Sumamed - (Pliva)
• Tailite - (Taiyang)
• Te Li Xin - (Hui Yin Bi)
• Tong Tai Qi Li - (Yi Kang)
• Tuo Neng - (Haixin)
• TuoQi - (Jinfeng)
• Wei Li Qing - (Qingfeng)
• Wei Lu De - (Jianfeng)
• Wei Zong - (Bikang)
• Weihong - (CSPC)
• Xi Le Xin - (Lukang Chenxin)
• Xi Mei - (C & O)
• Xin Da Kang - (Salubris)
• Xin Pu Rui - (Tianlong)
• Ya Rui - (Yatai)
• Yan Sha - (Xibaishou)
• Yi Nuo Da - (ShiJiaZhuang No 4)
• Yi Ou Qing - (Qilu)
• Yi Song - (De Zhou)
• Yi Xin - (Ankehengyi)
• Yin Pei Kang - (Jin Si Li)
• Yong Qi - (Shenlong)
• You Ni Ke - (Tong Yong Tong Meng)
• Yu Qi - (Limin)
• Zaiqi - (Simcere)
• Ze Qi - (Hicin)
• Zithromax - (Pfizer)
• Zithrome - (Hailing)
Czech Republic
• Azibiot - (KRKA)
• Azitrox - (Zentiva)
• Azyter - (Thea)
• Sumamed - (Teva)
• Zetamac - (Pfizer)
• Zitrocin - (Teva)
Denmark
• Azyter - (Thea)
• Zitromax - (Pfizer)
Finland
• Azyter - (Thea)
• Zithromax - (Pfizer)
France
• Azadose - (Pfizer)
• Azyter - (Thea)
• Ordipha - (Tonipharm)
• Zithromax - (Pfizer)
Germany
• Azithro - (Meda)
• Azithrobeta - (Betapharm)
• Azyter - (Thea)
• InfectoAzit - (Infectopharm)
• Ultreon - (Pfizer)
• Zithromax - (Pfizer)
Greece
• Alzirax - (Rafarm)
• Azibactron - (Cross)
• Azibiom - (Chemica)
• Azifarm - (Venifar)
• Azirox - (Pharmanel)
• Azirutec - (Zwitter)
• Azithral - (Cooper (Κοπερ))
• Azithrin - (Alet)
• Azitrolid - (Minerva (Μινερβα))
• Azivirus - (Verisfield)
• Azytan - (Medilat)
• Azyter - (Thea)
• Bezanin - (Iasis)
• Binozyt - (Sandoz)
• Ciroz - (Velka)
• Disithrom - (SJA)
• Flumax - (Gerolymatos)
• Goldamycin - (Leon)
• Gramokil - (Santa)
• Novozithron - (Novofarm (Νοβοφαρμ))
• Razimax - (Rafarm)
• Thoraxx - (Alapis)
• Throzimax - (Medilat)
• Zinfect - (Verisfield)
• Zithrobest - (Lyofin)
• Zithro-Due - (Vivax)
• Zithromax - (Pfizer)
• Zithroned - (Euroned)
• Zithropan - (Vocate)
• Zithroplus - (Balu)
• Zithrotel - (Anpharm (Ανφαρμ))
• Zithroxyn - (Help)
• Zitrax - (Genepharm)
• Zyramycin - (Leovan)
Hong Kong
• Athromax - (Quality)
• AZ-1 - (Nidoway)
• AZA - (XL)
• Azee - (Cipla)
• Azibact - (Swedish Trading)
• Azicine - (Stada)
• Azilide - (Yanny Medicines)
• Azimax - (Hovid)
• Azin - (Deltapharm)
• Azinix - (Julius Chen)
• Azirodin - (Julius Chen)
• Azirox - (Sincerity)
• Azitcin - (Wah Kin)
• Azithmax - (Vickmans)
• Azithrocin - (Eugenpharm)
• Azocin - (Eugenpharm)
• Aztrin - (Viewbest)
• Azure - (Eugenpharm)
• Azyter - (Thea)
• Binozyt - (Novartis)
• Clindal AZ - (APT)
• Euzimax - (Vickmans)
• Floctil - (Unison)
• Imexa - (Xepa-Soul Pattinson)
• Marzomax - (Vickmans)
• Nifomax - (Vickmans)
• Qualizith - (Quality)
• Sharozy - (Pharmasky)
• Sumamed - (Lee)
• Uni-Zitho - (Vickmans)
• Vick-Azithro - (Vickmans)
• Zarom - (Perfect Groups)
• Zathrin - (Star)
• Zetro - (Chariot)
• Zimax - (Unipharm)
• Zimycin - (Star)
• Zith - (Leon)
• Zithrin - (HealthCare PharmaScience)
• Zithromax - (Pfizer)
• Zmax - (Pfizer)
• Zotax - (Hovid)
• Zycin - (Natural Health)
Hungary
• Azi - (Sandoz)
• Azibiot - (KRKA)
• Azicid - (Generics)
• Aziwill - (Goodwill)
• Sumamed - (Teva)
• Zitinn - (Actavis)
• Zitrocin - (Teva)
• Zmax - (Pfizer)
India
• Acex - (Orion)
• Actimycin - (Venus)
• Alicin - (Allenge)
• A-OD - (Elisa)
• Apocin - (Apotex)
• Arcin - (Chemech)
• Arizith - (Arika)
• Arz - (Willow)
• Atm - (Indoco)
• Avzeth - (Positif)
• Az-1 - (Kopran)
• Azard - (Pharma-Tech)
• Azauk - (Aamorb)
• Azbir - (Birz)
• Azee - (Cipla)
• Azegud - (Biosync)
• Azeloc - (Symbiotic)
• Azforin - (Unichem)
• Azibact - (Ipca)
• Azibest - (Blue Cross)
• Azi-Big - (Bestochem)
• Azicip - (Cipla)
• Azicos - (Symbiosis)
• Azicure - (Radicura)
• Azid - (Indi)
• Azidraw - (Q Check)
• Azifast - (Ipca)
• Azifem - (Fem Care)
• Azifine - (Glenmark)
• Azigram - (United Lifecare)
• Azikab - (Lancer)
• Azikare - (Ankare)
• Azikil - (Maxo)
• Azileb - (Leben)
• Azilide - (Micro)
• Azilife - (Aqualife)
• Azilin - (Lincoln)
• Azilup - (Lupin)
• Azim - (BL)
• Azimac - (Mandar)
• Azimax - (Cipla)
• Azin - (Indo Pacific)
• Azina - (Zota)
• Azinex - (Aronex)
• Azinix - (Khandelwal)
• Azinova - (Bombay Tablet)
• Azintra - (Intra-Labs)
• Azintra-AX - (Intra-Labs)
• Aziom - (Zenon)
• Azipar - (Molekule)
• Azipokyn - (Misha)
• Azipos - (Aglowmed)
• Aziral - (Hiral)
• Azirid - (Armour)
• Aziriv - (East African)
• Azirock - (Ankom)
• Azis - (Taurus)
• Azisafe - (UniOrange)
• Azisara - (Sarabhai Piramal)
• Aziset - (Active)
• Azisia - (Willow)
• Azison - (Dr Alson)
• Azistar - (Sanify)
• Azisym - (Symbiosis)
• Azitas - (Intas)
• Aziter - (Gujarat Terce)
• Azith - (Zee)
• Azithom - (Om Biotec)
• Azithral - (Alembic)
• Azithral Jun - (Alembic)
• Azithro - (Ind-Swift)
• Azitone - (Keshav)
• Azitoz - (ATOZ)
• Azitrac - (Invision)
• Azitrin - (Pharmatech)
• Azitrop - (Elfin)
• Azitsa - (Akesiss)
• Azitus - (Zuventus)
• Azivar - (Zota)
• Aziwin - (Bal)
• Aziwok - (Wockhardt)
• Azix - (Alicon)
• Azla - (Candor)
• Azmag - (Magnus)
• Azmic - (Emar)
• Azobac - (Medinova)
• Azolid - (Scoshia)
• Azolife - (Dexter)
• Azom - (Finecure)
• Azomax - (Max)
• Azone - (NB)
• Azopet - (Vista)
• Azostar - (Gentech)
• Azras - (Rass)
• Azrea - (Cinerea)
• Azro - (Abbott)
• Azro AM - (Abbott)
• Aztin - (Laksun)
• Aztus - (Emcure)
• Azvig - (Madhav)
• Azy - (Uniroyal)
• Azylin - (Zota)
• Azysafe - (Overseas)
• Azystate - (Haledew)
• Azyxin - (Centaur)
• Azyxin Plus - (Centaur)
• Azza - (Wintech)
• Bezit - (Plus)
• Bio-AZ - (Biomax)
• Cazita - (Admac)
• Corzi - (DWD)
• Cumycin - (Curex)
• Dazy - (Daksh)
• Elgram - (Captab)
• Elzee - (Elder)
• Ertycin - (Abbott)
• Eszit - (Ester)
• Ezith - (Evershine)
• Flaag - (Flamingo)
• Forit - (Health Care)
• Fydozith - (Xieon)
• Gitro - (Plus)
• G-Thro - (Globus)
• Hizy - (Hos & Ins)
• Infurox - (Servocare)
• Itha - (Alna)
• I-Thro - (Zubit)
• Jocin - (DR Johns)
• Kanny - (Kalpataru)
• Laz - (Hetero)
• Laz-AX - (Hetero)
• Lazith - (Admac)
• Lethro - (Forgo)
• LG-Thral - (Anvik)
• Loromycin - (Novartis)
• L-Thro - (Lexus)
• Macrosafe - (MSN)
• Macrotar - (Torrent)
• Maxazi - (United Biotech)
• Myza - (Esma)
• Nizithro - (Neiss)
• Nodycin - (Nodysis)
• Orflaz Kit - (Aristo)
• Saf Kit - (Biochem)
• Zithrocin - (Biochem)
• Zycin - (Cadila)
Indonesia
• Aziwin - (Aventis)
• Azomax - (Dexa)
• Aztrin - (Pharos)
• Azyter - (Kalbe Vision)
• Binozyt - (Sandoz)
• Ethrimax - (Ethica)
• Maxmor - (Mahakam Beta)
• Mezatrin - (Sanbe)
• Sohomac - (Ethica)
• Trozin - (Tempo Scan Pacific)
• Zarom - (Pyridam)
• Zibramax - (Guardian)
• Zicho - (Nicholas)
• Zifin - (Yarindo)
• Zistic - (Bernofarm)
• Zithrax - (Kalbe)
• Zithromax - (Pfizer)
• Zitrolin - (Otto)
• Zycin - (Interbat)
Ireland
• Azromax - (Gerard)
• Azyter - (Thea)
• Zedbac - (Aspire)
• Zithromax - (Pfizer)
Israel
• Azenil - (Pfizer)
• Zeto - (Trima)
• Zithromax - (Pfizer)
• Zmax - (Pfizer)
Italy
• Azitrocin - (Pfizer)
• Batif - (Epifarma)
• Ribotrex - (Pierre Fabre)
• Trozocina - (Sigma-Tau)
• Zindel - (SoSe)
• Zitrobiotic - (Epifarma)
• Zitromax - (Pfizer)
Japan
• Zithromac - (Pfizer)
Malaysia
• Azicine - (Stada)
• Azimax - (Hovid)
• Azithro - (M & H)
• Binozyt - (Sandoz)
• Floctil - (Unison)
• Imexa - (Xepa-Soul Pattinson)
• Zithrolide - (Pharmaniaga)
• Zithromax - (Pfizer)
• Zmax - (Pfizer)
• Zynomax - (CCM)
Mexico
• Amsati - (Amsa)
• Atoxitom - (Landsteiner)
• Azibiot - (Mavi)
• Azidral - (Silanes)
• Aziphar - (Alpharma)
• Aziteva - (Teva)
• Azitrocin - (Pfizer)
• Azitrohexal - (Sandoz)
• Azo-Max - (Unipharm)
• Azotive - (Aspen)
• Aztrogecin - (Lakeside)
• Charyn - (Wermar)
• Craztronin - (Raam)
• Koptin - (Chinoin)
• Macrozit - (Liomont)
• Marzivag - (Novag)
• Medatz - (Bajamed)
• Mizotryn - (Liferpal)
• Sicalan - (Loeffler)
• Texis - (Atlantis)
• Tromicina - (Offenbach)
• Truxa - (Asofarma)
• Zertalin - (Collins)
• Zithran - (Ranbaxy)
• Zitroflam - (Rimsa)
• Zitroken - (Kendrick)
Netherlands
• Azacleus - (Nucleus)
• Azitro - (Merck)
• Azyter - (Thea)
• Bazyt - (Thea)
• Merckazitro - (Merck)
• Nucaza - (Nucleus)
• Zithromax - (Pfizer)
New Zealand
• Zithromax - (Pfizer)
Norway
• Azitromax - (Pfizer)
• Azyter - (Thea)
Philippines
• Aza-500 - (XL)
• Azeecor - (Akums)
• Azeemycin - (SRS)
• Azemax - (Cathay)
• Azi - (InnoGen)
• Azimax - (Twilight Litaka)
• Azin - (ACME)
• Azithro - (Natrapharm)
• Azithrogen - (Nutramedica)
• Azitrocin - (Mundipharma)
• Azo - (Mediwin)
• Azomycin - (Royale)
• Aztro - (Stallion)
• Azyth - (Sandoz)
• Decantin - (Lok-Beta)
• Geozit - (Geofman)
• Jazit - (Somatec)
• Macromax - (Domesco)
• Macrozyth - (Cipla)
• OD Mac - (Farma Iberica)
• Pediazith - (Medlink)
• Romzin - (Biopharma)
• Sitimax - (CSPC)
• Thromaxin - (ACME)
• Trozin - (Mercury)
• Wiltrozin - (Hizon)
• Zenith - (Pediatrica)
• Zithran - (Lloyd)
• Zithrocare - (Khriz)
• Zithrocin - (Pharma Nutria)
• Zithromax - (Pfizer)
• Zithrozan - (Biopharma)
• Zit-Od - (PSA)
• Zmax - (Pfizer)
Poland
• Abiazyt - (Artespharm)
• Azibiot - (KRKA)
• Azigen - (Generics)
• Azimycin - (Polfa Tarchomin)
• AziTeva - (Teva)
• Azitrin - (Genexo)
• AzitroLEK - (Sandoz)
• Azitro-Mepha - (Mepha)
• Azitrox - (Zentiva)
• Azycyna - (Adamed)
• Azytact - (Tactica)
• Azyter - (Thea)
• Bactrazol - (Teva)
• Canbiox - (Apotex)
• Macromax - (PharmaSwiss)
• Nobaxin - (Lek-Am)
• Oranex - (Farmacom)
• Sumamed - (Teva)
• Zetamax - (Pfizer)
Portugal
• 3Z - (Jaba Recordati)
• Arzomicina - (APS)
• Azimax - (Pfizer)
• Azimed - (Daquimed)
• Aziton - (Labesfal)
• Azitrix - (Pentafarma)
• Azixratio - (Ratiopharm)
• Azyter - (Thea)
• Biozitra - (BioSaude)
• Gigatrom - (Medilusa)
• Imrotim - (Statim)
• Lazitrom - (Azevedos)
• Neofarmiz - (Farmoz)
• Unizitro - (Tecnimede)
• Vascin - (Helm)
• Zithromax - (Pfizer)
• Zitrina - (Decomed)
• Zitrozina - (Sidefarma)
Russian Federation
• Azicid - (Zentiva)
• Azimycin - (Micro)
• Azithrox - (Farmstandart)
• Azithrus - (Sintez)
• Azitral - (Shreya)
• Aziwok - (Wockhardt)
• Azydrop - (Thea)
• Ecomed - (Avva)
• Hemomycin - (Hemofarm)
• Safocid - (Stada)
• Sumaklid - (Biosintez)
• Sumamecin - (Obolenskoe)
• Sumamed - (Pliva)
• Sumamox - (Oxford Laboratories)
• Sumatrolid - (Ozone)
• Sumazid - (Bryntsalov)
• Tremak - (Sanovel)
• Zetamax - (Pfizer)
• ZI-Factor - (Veropharm)
• Zithrocin - (Unique)
• Zitnob - (Nobel)
• Zitrolid - (Valenta)
Singapore
• Azimax - (Hovid)
• AZmycin - (Invent)
• Binozyt - (Sandoz)
• Zithromax - (Pfizer)
• Zmax - (Pfizer)
South Africa
• Azimax - (Teva)
• Binozyt - (Zydus)
• Clamelle - (Cipla-Medpro)
• Jubazi - (LeBasi)
• Ultreon - (Pfizer)
• Varimax - (MDI)
• Zeemide - (Ascendis)
• Zithrogen - (Mylan)
• Zithromax - (Pfizer)
Spain
• Altezym - (Alter)
• Aratro - (Arafarma)
• Azydrop - (Thea)
• Goxil - (Pfizer)
• Pefloden - (Vita)
• Toraseptol - (Warner Chilcott)
• Vinzam - (Almirall)
• Zentavion - (Warner Chilcott)
• Zitromax - (Pfizer)
Sweden
• Azitromax - (Pfizer)
• Azyter - (Thea)
Switzerland
• Azitro - (Acino)
• Zithromax - (Pfizer)
Thailand
• Azith - (Siam Bheasach)
• Azithrin - (TO-Chemicals)
• Azithro - (M & H)
• Azycin - (GPO)
• Azyter - (Thea)
• Binozyt - (Sandoz)
• Floctil - (Unison)
• Meithromax - (Meiji)
• Onzet - (M & H)
• Zithromax - (Pfizer)
• Zmax - (Pfizer)
Turkey
• Azacid - (Fako)
• Azax - (Nobel)
• Azeltin - (Biofarma)
• Azitro - (Deva)
• Azitrotek - (Deva)
• Azomax - (Kocak)
• Azro - (Zentiva)
• Azyter - (Thea)
• Tremac - (Sanovel)
• Zitromax - (Pfizer)
• Zitrotek - (Pfizer)
Ukraine
• Azax - (Nobel)
• Azibiot - (KRKA)
• Azicin - (Darnitsa)
• Azimed - (Arterium)
• Azinort - (Norton)
• Azithral - (Alembic)
• Azithro - (Sandoz)
• Azithromax - (Pharmascience)
• Azitrox - (Zentiva)
• Aziwok - (Wockhardt)
• Azo - (Tulip)
• Azro - (Eczacibasi)
• Hemomicin - (Hemofarm)
• Ormax - (Sperko)
• Sumamed - (Teva)
• Zatrin - (Euro Lifecare)
• Zetamax - (Pfizer)
• Ziromin - (World Medicine)
• Zithrocin - (Unique)
• Zithrolex - (October Pharma)
• Zomax - (Hikma)
• Zyomicin - (Kusum)
United Arab Emirates
• Azomycin - (Julphar)
United Kingdom
• Azyter - (Spectrum)
• Clamelle - (Actavis)
• Zedbac - (Aspire)
• Zithromax - (Pfizer)
Venezuela
• Amizin - (Giempi)
• Amovin - (Cofasa)
• Aruzilina - (Leti)
• Arzomidol - (Dollder)
• Atromizin - (Cafar)
• Azigram - (Vivax)
• Azimakrol - (Roemmers-Klinos)
• Azitrom - (SM)
• Azitromin - (Farma)
• Binozyt - (Sandoz)
• Ricilina - (Gynopharm)
• Saver - (Elmor)
• Surgot - (Klinos)
• Tromizid - (Medley)
• Zitromax - (Pfizer)
• Zival - (Valmor)
• Zocin - (Biogalenic)
Copyright © 2020 Elsevier Inc. All rights reserved.
